Attached files
file | filename |
---|---|
EX-32.1 - EX-32.1 - IDERA PHARMACEUTICALS, INC. | b86105exv32w1.htm |
EX-31.2 - EX-31.2 - IDERA PHARMACEUTICALS, INC. | b86105exv31w2.htm |
EX-32.2 - EX-32.2 - IDERA PHARMACEUTICALS, INC. | b86105exv32w2.htm |
EX-10.1 - EX-10.1 - IDERA PHARMACEUTICALS, INC. | b86105exv10w1.htm |
EX-31.1 - EX-31.1 - IDERA PHARMACEUTICALS, INC. | b86105exv31w1.htm |
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
þ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended March 31, 2011,
or
o | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For transition period from to . |
Commission File Number: 001-31918
IDERA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware | 04-3072298 | |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
167 Sidney Street Cambridge, Massachusetts (Address of principal executive offices) |
02139 (zip code) |
(617) 679-5500
(Registrants telephone number, including area code)
(Registrants telephone number, including area code)
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed
by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or
for such shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days.
Yes þ No o
Indicate by check mark whether the registrant has submitted electronically and posted on its
corporate Web site, if any, every Interactive Data File required to be submitted and posted
pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months
(or for such shorter period that the registrant was required to submit and post such files). Yes
o No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated
filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large
accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the
Exchange Act. (Check one):
Large accelerated filer o | Accelerated filer þ | Non-accelerated filer o (Do not check if a smaller reporting company) | Smaller reporting company o |
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of
the Exchange Act). Yes o No þ
Common Stock, par value $.001 per share | 27,615,933 | |
Class | Outstanding as of April 30, 2011 |
IDERA PHARMACEUTICALS, INC.
FORM 10-Q
INDEX
FORM 10-Q
INDEX
IMO® and Idera® are our trademarks. All other trademarks and service
marks appearing in this Quarterly Report on Form 10-Q are the property of their respective owners.
i
Table of Contents
FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended. All statements, other than statements of historical fact, included or
incorporated in this report regarding our strategy, future operations, collaborations, intellectual
property, financial position, future revenues, projected costs, prospects, plans, and objectives of
management are forward-looking statements. The words believes, anticipates, estimates,
plans, expects, intends, may, could, should, potential, likely, projects,
continue, will, and would and similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain these identifying words. We cannot
guarantee that we actually will achieve the plans, intentions or expectations disclosed in our
forward-looking statements and you should not place undue reliance on our forward-looking
statements. There are a number of important factors that could cause our actual results to differ
materially from those indicated or implied by forward-looking statements. These important factors
include those set forth below under Part II, Item 1A Risk Factors. These factors and the other
cautionary statements made in this Quarterly Report on Form 10-Q should be read as being applicable
to all related forward-looking statements whenever they appear in this Quarterly Report on Form
10-Q. In addition, any forward-looking statements represent our estimates only as of the date that
this Quarterly Report on Form 10-Q is filed with the Securities and Exchange Commission and should
not be relied upon as representing our estimates as of any subsequent date. We do not assume any
obligation to update any forward-looking statements. We disclaim any intention or obligation to
update or revise any forward-looking statement, whether as a result of new information, future
events or otherwise.
ii
Table of Contents
PART I FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
IDERA PHARMACEUTICALS, INC.
CONDENSED BALANCE SHEETS
(UNAUDITED)
(UNAUDITED)
March 31, | December 31, | |||||||
(In thousands, except per share amounts) | 2011 | 2010 | ||||||
ASSETS |
||||||||
Current assets: |
||||||||
Cash and cash equivalents |
$ | 21,109 | $ | 17,008 | ||||
Short-term investments |
7,237 | 17,635 | ||||||
Receivables |
9 | 2 | ||||||
Prepaid expenses and other current assets |
1,167 | 995 | ||||||
Total current assets |
29,522 | 35,640 | ||||||
Property and equipment, net |
820 | 930 | ||||||
Restricted cash, net of current portion |
311 | 311 | ||||||
Total assets |
$ | 30,653 | $ | 36,881 | ||||
LIABILITIES AND STOCKHOLDERS EQUITY |
||||||||
Current liabilities: |
||||||||
Accounts payable |
$ | 968 | $ | 1,757 | ||||
Accrued expenses |
2,501 | 1,775 | ||||||
Current portion of capital lease |
4 | 8 | ||||||
Total current liabilities |
3,473 | 3,540 | ||||||
Other liabilities |
231 | 240 | ||||||
Total liabilities |
3,704 | 3,780 | ||||||
Commitments and contingencies |
||||||||
Stockholders equity: |
||||||||
Preferred stock, $0.01 par value,
Authorized 5,000 shares
Series A convertible preferred stock, Designated 1,500 shares,
Issued and outstanding 1 share |
| | ||||||
Common stock, $0.001 par value,
Authorized 70,000 shares
Issued and outstanding 27,611 and 27,596 shares at March 31, 2011 and
December 31, 2010, respectively |
28 | 28 | ||||||
Additional paid-in capital |
385,404 | 384,702 | ||||||
Accumulated deficit |
(358,487 | ) | (351,642 | ) | ||||
Accumulated other comprehensive income |
4 | 13 | ||||||
Total stockholders equity |
26,949 | 33,101 | ||||||
Total liabilities and stockholders equity |
$ | 30,653 | $ | 36,881 | ||||
The accompanying notes are an integral part of these financial statements.
1
Table of Contents
IDERA PHARMACEUTICALS, INC.
CONDENSED STATEMENTS OF OPERATIONS
(UNAUDITED)
(UNAUDITED)
Three Months Ended | ||||||||
March 31, | ||||||||
(In thousands, except per share amounts) | 2011 | 2010 | ||||||
Alliance revenue |
$ | 8 | $ | 5,577 | ||||
Operating expenses: |
||||||||
Research and development |
4,553 | 4,586 | ||||||
General and administrative |
2,286 | 2,732 | ||||||
Total operating expenses |
6,839 | 7,318 | ||||||
Loss from operations |
(6,831 | ) | (1,741 | ) | ||||
Other income (expense): |
||||||||
Investment income, net |
21 | 26 | ||||||
Foreign currency exchange loss |
(35 | ) | (228 | ) | ||||
Net loss |
$ | (6,845 | ) | $ | (1,943 | ) | ||
Basic and diluted net loss per share (Note 12): |
$ | (0.25 | ) | $ | (0.08 | ) | ||
Shares used in computing basic and diluted net
loss per common share |
27,604 | 23,462 | ||||||
The accompanying notes are an integral part of these financial statements.
2
Table of Contents
IDERA PHARMACEUTICALS, INC.
CONDENSED STATEMENTS OF CASH FLOWS
(UNAUDITED)
(UNAUDITED)
Three Months Ended | ||||||||
March 31, | ||||||||
(In thousands) | 2011 | 2010 | ||||||
Cash Flows from Operating Activities: |
||||||||
Net loss |
$ | (6,845 | ) | $ | (1,943 | ) | ||
Adjustments to reconcile net loss to net cash used in operating activities |
||||||||
Stock-based compensation |
660 | 1,173 | ||||||
Non-employee stock option expense |
6 | 14 | ||||||
Depreciation expense |
128 | 144 | ||||||
Amortization of investment premiums |
29 | 49 | ||||||
Issuance of common stock for services rendered |
13 | 1 | ||||||
Changes in operating assets and liabilities: |
||||||||
Accounts receivable |
(7 | ) | 4,455 | |||||
Prepaid expenses and other current assets |
(172 | ) | (1,583 | ) | ||||
Accounts payable, accrued expenses and other liabilities |
(72 | ) | 734 | |||||
Deferred revenue |
| (5,547 | ) | |||||
Net cash used in operating activities |
(6,260 | ) | (2,503 | ) | ||||
Cash Flows from Investing Activities: |
||||||||
Purchases of available-for-sale securities |
(1,025 | ) | (8,106 | ) | ||||
Proceeds from maturity of available-for-sale securities |
11,385 | | ||||||
Purchases of property and equipment |
(18 | ) | (60 | ) | ||||
Net cash provided by (used in) investing activities |
10,342 | (8,166 | ) | |||||
Cash Flows from Financing Activities: |
||||||||
Proceeds from exercise of common stock options and employee stock purchases |
23 | 39 | ||||||
Payments on capital lease |
(4 | ) | (5 | ) | ||||
Net cash provided by financing activities |
19 | 34 | ||||||
Net increase (decrease) in cash and cash equivalents |
4,101 | (10,635 | ) | |||||
Cash and cash equivalents, beginning of period |
17,008 | 25,471 | ||||||
Cash and cash equivalents, end of period |
$ | 21,109 | $ | 14,836 | ||||
The accompanying notes are an integral part of these financial statements.
3
Table of Contents
IDERA PHARMACEUTICALS, INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS
March 31, 2011
(UNAUDITED)
March 31, 2011
(UNAUDITED)
(1) (a) Organization
Idera Pharmaceuticals, Inc. (Idera or the Company) is a biotechnology company engaged in
the discovery and development of DNA-and RNA-based drug candidates targeted to Toll-Like Receptors,
or TLRs, to treat infectious diseases, autoimmune and inflammatory diseases, cancer, and
respiratory diseases, and for use as vaccine adjuvants. Drug candidates are compounds that the
Company is developing and that have not been approved for any commercial use. TLRs are specific
receptors present in immune system cells that recognize the DNA or RNA of bacteria or viruses and
initiate an immune response. Relying on its expertise in DNA and RNA chemistry, the Company has
designed and created proprietary TLR agonists and antagonists to modulate immune responses. A TLR
agonist is a compound that stimulates an immune response through the targeted TLR. A TLR antagonist
is a compound that blocks activation of an immune response through the targeted TLR.
Ideras business strategy is to advance applications of its TLR-targeted drug candidates in
multiple disease areas simultaneously. The Company is advancing some of these applications through
internal programs, and it seeks to advance other applications through collaborative alliances with
pharmaceutical companies. Collaborators provide the necessary resources and drug development
experience to advance the Companys compounds in their programs. Upfront payments and milestone
payments received from collaborations help to provide the Company with the financial resources for
its internal research and development programs.
The Companys internal programs are focused on developing TLR-targeted drug candidates for the
potential treatment of infectious diseases, autoimmune and inflammatory diseases, cancer, and
respiratory diseases, and for use as vaccine adjuvants. The Company also is advancing its gene
silencing oligonucleotide, or GSO, technology for potential application as research reagents and
as therapeutic agents.
In addition to its internal programs, the Company is currently collaborating with two
pharmaceutical companies to advance other applications of its TLR-targeted compounds. The Company
is collaborating with Merck KGaA for the use of TLR9 agonists in cancer treatment, excluding cancer
vaccines. Merck KGaA is conducting clinical trials of IMO-2055, which Merck KGaA refers to as EMD
1201081, in combination with other cancer therapy agents in cancer indications including a Phase 2
clinical trial in squamous cell carcinoma of the head and neck. The Company also is collaborating
with Merck Sharp & Dohme Corp. formerly Merck & Co., Inc. which is referred to herein as Merck, for
the use of TLR7, TLR8, and TLR9 agonists as vaccine adjuvants in the fields of cancer, infectious
diseases, and Alzheimers disease. Merck KGaA and Merck are not related.
At March 31, 2011, the Company had an accumulated deficit of $358.5 million. The Company
expects to incur substantial operating losses in future periods. The Company does not expect to
generate significant product revenue or royalties until it successfully completes development and
obtains marketing approval for drug candidates, either alone or in collaborations with third
parties, which it expects will take a number of years. In order to commercialize its drug
candidates, the Company needs to complete clinical development and to comply with
comprehensive regulatory requirements. In 2011, the Company expects that its research and
development expenses will be lower than its research and development expenses in 2010 reflecting
the completion of multiple Phase 1 clinical trials in 2010 and the Companys clinical development
plans for 2011.
The Company had cash, cash equivalents, and investments of $28.3 million at March 31, 2011.
The Company believes that its existing cash, cash equivalents, and investments will be sufficient
to fund its operations at least through March 31, 2012 based on its current operating plan. The
Company expects to need to raise additional funds in order to operate its business beyond March 31,
2012. Additional financing may not be available to the Company when it needs it or may not be
available on favorable terms.
4
Table of Contents
The Company is subject to a number of risks and uncertainties similar to those of other
companies of the same size within the biotechnology industry, such as uncertainty of success and
timeliness of development, including clinical trial outcomes, uncertainty of funding, and history
of operating losses.
(b) New Accounting Pronouncements
The Company adopted Financial Accounting Standards Board, or FASB, Accounting Standard Update
No. 2009-13, Multiple-Element Revenue Arrangements (ASU No. 2009-13) on January 1, 2011. ASU
No. 2009-13 updates the existing multiple-element revenue arrangements guidance currently included
in Accounting Standards Codification No. 605-25 in two ways. The first change relates to the
determination of when the individual deliverables included in multiple-element arrangements may be
treated as separate units of accounting. This is significant since it may result in the requirement
to separate more deliverables within an arrangement, ultimately leading to less revenue deferral.
The second change modifies the manner in which the transaction consideration is allocated across
the separately identified deliverables. The Company is applying ASU No. 2009-13 prospectively to
arrangements entered into or materially modified after the adoption date. Since the Companys
period of continuing involvement in the research portions of all of its current collaboration
agreements was completed during 2010 and since all of the up-front payments received under these
collaborations were fully amortized as of December 31, 2010, the adoption of ASU No. 2009-13 had no
effect on the Companys financial position and results of operations through March 31, 2011. The
effect that ASU No. 2009-13 may have on the Companys policy for recognizing revenue under any
future collaboration agreements will depend upon the terms of those future collaboration
agreements, if any.
The Company adopted FASB Accounting Standard Update No. 2010-17, Milestone Method of Revenue
Recognition (ASU No. 2010-17) on January 1, 2011. ASU No. 2010-17 provides guidance on defining
a milestone and determining when it may be appropriate to apply the milestone method of revenue
recognition for research or development transactions. The Company is applying ASU No. 2010-17
prospectively to arrangements entered into or materially modified after the adoption date. Since
the Company did not earn any milestones during the first quarter of 2011, the adoption of ASU No.
2010-17 has had no effect on the Companys financial position and results of operations through
March 31, 2011. Since the Company used a similar method of recognizing milestone revenue prior to
adopting ASU No. 2010-17, the Company does not expect that the adoption of ASU No. 2010-17 will
have a significant effect on its policy for recognizing revenue on any milestones that it receives
in future periods.
(2) Unaudited Interim Financial Statements
The accompanying unaudited financial statements included herein have been prepared by the
Company in accordance with United States generally accepted accounting principles for interim
financial information and pursuant to the rules and regulations of the Securities and Exchange
Commission (the SEC). Accordingly, certain information and footnote disclosures normally included
in financial statements prepared in accordance with United States generally accepted accounting
principles have been condensed or omitted pursuant to such rules and regulations. In the opinion of
management, all adjustments, consisting of normal recurring adjustments, and disclosures considered
necessary for a fair presentation of interim period results have been included. Interim results for
the three-month period ended March 31, 2011 are not necessarily indicative of results that may be
expected for the year ended December 31, 2011. For further information, refer to the financial
statements and footnotes thereto included in the Companys Annual Report on Form 10-K for the
fiscal year ended December 31, 2010, which was filed with the SEC on March 10, 2011.
5
Table of Contents
(3) Cash, Cash Equivalents and Short-Term Investments
The Company considers all highly liquid investments with maturities of 90 days or less when
purchased to be cash equivalents. Cash and cash equivalents at March 31, 2011 and December 31, 2010
consisted of cash and money market funds.
Management determines the appropriate classification of marketable securities at the time of
purchase. Investments that the Company does not have the positive intent to hold to maturity are
classified as available-for-sale and reported at fair market value. Unrealized gains and losses
associated with available-for-sale investments are recorded in Accumulated other comprehensive
income on the accompanying balance sheets. The amortization of premiums and accretion of
discounts, and any realized gains and losses and declines in value judged to be
other-than-temporary, and interest and dividends for all available-for-sale securities are included
in Investment income, net on the accompanying statements of operations. Investments that the
Company intends to hold to maturity are classified as held-to-maturity investments. The Company
had no held-to-maturity investments at either March 31, 2011 or December 31, 2010. The cost of
securities sold is based on the specific identification method.
The Company had no realized gains or losses from available-for-sale securities in the three
months ended March 31, 2011 and 2010. There were no losses or other-than-temporary declines in
value included in Investment income, net for any securities for the three months ended March 31,
2011 and 2010. The Company had no auction rate securities as of March 31, 2011 and December 31,
2010.
The Companys available-for-sale short-term investments consisted of the following at March
31, 2011 and December 31, 2010:
March 31, 2011 | ||||||||||||||||
Gross | Gross | Estimated | ||||||||||||||
Unrealized | Unrealized | Fair | ||||||||||||||
(In thousands) | Cost | (Losses) | Gains | Value | ||||||||||||
Corporate bonds due in one year or less |
$ | 4,232 | $ | | $ | 3 | $ | 4,235 | ||||||||
U.S. government bonds dues in one year or less |
3,001 | | 1 | 3,002 | ||||||||||||
Total |
$ | 7,233 | $ | | $ | 4 | $ | 7,237 | ||||||||
December 31, 2010 | ||||||||||||||||
Gross | Gross | Estimated | ||||||||||||||
Unrealized | Unrealized | Fair | ||||||||||||||
(In thousands) | Cost | (Losses) | Gains | Value | ||||||||||||
Agency bonds due in one year or less |
$ | 3,201 | $ | | $ | | $ | 3,201 | ||||||||
Corporate bonds due in one year or less |
3,214 | | 4 | 3,218 | ||||||||||||
U.S. government bonds dues in one year or less |
11,207 | | 9 | 11,216 | ||||||||||||
Total |
$ | 17,622 | $ | | $ | 13 | $ | 17,635 | ||||||||
(4) Fair Value of Assets and Liabilities
The Company measures fair value at the price that would be received to sell an asset or paid
to transfer a liability in an orderly transaction between market participants at the measurement
date using assumptions that market participants would use in pricing the asset or liability (the
inputs) into a three-tier fair value hierarchy. This fair value hierarchy gives the highest
priority (Level 1) to quoted prices in active markets for identical assets or liabilities and the
lowest priority (Level 3) to unobservable inputs in which little or no market data exists,
requiring companies to develop their own assumptions. Observable inputs that do not meet the
criteria of Level 1, and include quoted prices for similar assets or liabilities in active markets
or quoted prices for identical assets and liabilities in markets that are not active, are
categorized as Level 2. Level 3 inputs are those that reflect the Companys estimates about the
assumptions market participants would use in pricing the asset or liability, based on the best
information available in the circumstances. Valuation techniques for assets and liabilities
measured using Level 3 inputs may include unobservable inputs such as projections, estimates and
managements interpretation of current market data.
These unobservable Level 3 inputs are only utilized to the extent that observable inputs are
not available or cost-effective to obtain.
6
Table of Contents
The table below presents the assets and liabilities measured at fair value on a recurring
basis at March 31, 2011 categorized by the level of inputs used in the valuation of each asset and
liability.
Quoted | ||||||||||||||||
Prices | ||||||||||||||||
in Active | ||||||||||||||||
Markets | Significant | |||||||||||||||
for Identical | Other | Significant | ||||||||||||||
Assets or | Observable | Unobservable | ||||||||||||||
Liabilities | Inputs | Inputs | ||||||||||||||
(In thousands) | Total | (Level 1) | (Level 2) | (Level 3) | ||||||||||||
Assets |
||||||||||||||||
Money market fund |
$ | 19,911 | $ | 19,911 | $ | | $ | | ||||||||
Other cash equivalents |
1,000 | | 1,000 | |||||||||||||
Short-term investments |
7,237 | 3,002 | 4,235 | | ||||||||||||
Total |
$ | 28,148 | $ | 22,913 | $ | 5,235 | $ | | ||||||||
Liabilities |
$ | | $ | | $ | | $ | | ||||||||
The Level 1 assets consist of money market funds and U.S. Government bond investments, both of
which are actively traded daily. The Level 2 assets consist of corporate bond investments whose
fair value is generally determined from quoted market prices received from pricing services based
upon quoted prices from active markets and/or other significant observable market transactions at
fair value. Since these prices may not represent actual transactions of identical securities, they
are classified as Level 2. Since all investments are classified as available-for-sale securities,
any unrealized gains or losses are recorded in accumulated other comprehensive income or loss
within stockholders equity on the balance sheet. The Company did not elect to measure any other
financial assets or liabilities at fair value. See Note (3).
(5) Property and Equipment
At March 31, 2011 and December 31, 2010, net property and equipment at cost consisted of the
following:
March 31, | December 31, | |||||||
(In thousands) | 2011 | 2010 | ||||||
Leasehold improvements |
$ | 525 | $ | 515 | ||||
Laboratory equipment and other |
2,897 | 2,889 | ||||||
Total property and equipment, at cost |
3,422 | 3,404 | ||||||
Less: accumulated depreciation |
(2,602 | ) | (2,474 | ) | ||||
Property and equipment, net |
$ | 820 | $ | 930 | ||||
As of March 31, 2011 and December 31, 2010, laboratory equipment and other included
approximately $79,000 of office equipment financed under capital leases with accumulated
depreciation of approximately $60,000 and $56,000, respectively.
Depreciation expense, which includes amortization of assets recorded under capital leases, was
approximately $128,000 and $144,000 in the three months ended March 31, 2011 and 2010,
respectively.
(6) Restricted Cash
As part of the Companys lease arrangement for its office and laboratory facility, the Company
was required to restrict $619,000 of cash for a security deposit. The restricted cash was reduced
by a total of approximately $206,000 upon the second and third anniversaries of the June 2007 lease
commencement date. As a result, at March 31, 2011, restricted cash was $413,000. The restricted
cash is held in certificates of deposit securing a line of credit for the lessor. The restricted
cash is expected to be further reduced by approximately $102,000 upon the fourth
anniversary of the lease commencement date, subject to certain conditions. As a result, $102,000 of
the $413,000 has been classified in Prepaid expenses and other current assets.
7
Table of Contents
(7) Comprehensive Loss
The following table includes the components of comprehensive loss for the three months ended
March 31, 2011 and 2010.
Three months ended March 31, | ||||||||
(In thousands) | 2011 | 2010 | ||||||
Net loss |
$ | (6,845 | ) | $ | (1,943 | ) | ||
Other comprehensive (loss) income |
(9 | ) | 17 | |||||
Total comprehensive loss |
$ | (6,854 | ) | $ | (1,926 | ) | ||
Other comprehensive (loss) income represents the change in the net unrealized gains (losses) on
available-for-sale investments during the period.
(8) Revenue Recognition
An important part of the Companys business strategy is to enter into research and development
collaborations with biotechnology and pharmaceutical corporations that bring expertise and
resources to the potential research and development and commercialization of drugs based on the
Companys technology. Under the Companys research and development collaborations, the Company has
generally licensed specified portions of its intellectual property and provided research and
development services to the collaborator during the period of continued involvement in the early
portion of the collaborations. The collaborators have generally been responsible for drug
development activities initiated after the collaboration is effective. The collaborators are also
generally responsible for any commercialization activities that may be initiated if any of the drug
candidates receive marketing approval from the appropriate regulatory authority.
Under
the Companys existing collaborative arrangements, the Company
has received non-refundable license fees, milestone payments, reimbursements of certain internal and
external research and development expenses and patent-related
expenses. The Company is also entitled to receive royalties on product
sales. The Company classifies all of these amounts as revenue in its statement of operations since
it considers licensing intellectual property and providing research and development and
patent-related services to be part of its central business operations. In the three months ended
March 31, 2010, alliance revenue consisted primarily of revenue recognized under the Merck KGaA and
Merck collaborations. Since the Company completed the research portions of these collaborations
during 2010, all of the upfront license fee payments were fully amortized and recognized by
December 2010. Consequently, the Company did not recognize any revenue under the Merck KGaA and
Merck collaborations during the three months ended March 31, 2011. Alliance revenue for the three
months ended March 31, 2011 and 2010, including revenue recognized under the Companys
collaborative arrangements with Merck KGaA and Merck during the 2010 period, was as follows:
Three Months Ended March 31, | ||||||||
(In thousands) | 2011 | 2010 | ||||||
Collaboration revenue |
||||||||
Merck KGaA |
$ | | $ | 4,303 | ||||
Merck |
| 1,250 | ||||||
| 5,553 | |||||||
Other revenue |
8 | 24 | ||||||
Total alliance revenue |
$ | 8 | $ | 5,577 | ||||
During the three months ended March 31, 2010, the Company incurred approximately $15,000 in
third-party expenses in connection with its collaborative arrangements. The Company did not incur
any such expenses in the
corresponding 2011 period. These third party expenses are classified as research and
development and general and administrative expenses in the Companys statement of operations.
When evaluating multiple element arrangements, the Company considers whether each deliverable
of the arrangement represents a separate unit of accounting based on specified criteria such as
whether the deliverable has
8
Table of Contents
standalone
value to the collaborator. Any fixed or determinable
payments that the Company expects to receive under the arrangement are allocated among the separate
units of accounting and the appropriate revenue recognition criteria are applied to each of these
separate units. Any item that does not qualify as a separate unit of accounting is combined with
other appropriate items and the combined deliverable is treated as a separate unit of accounting.
The
allocation of fixed or determinable payments to the separate units of accounting is based
on the relative-selling-price method which is based on the following hierarchy used in determining
the selling price for each unit of accounting: (1) Vendor specific objective evidence, or VSOE, -
the price at which the item is regularly sold by the vendor on a standalone basis, is the preferred
method. (2) Third-party evidence, or TPE, of vendors selling similar goods to similarly situated
customers on a standalone basis if VSOE of selling price of a product or service is not available.
(3) Best estimate of selling price, or BESP, if neither VSOE nor TPE of selling price of a
product or service is available.
The timing of revenue recognition from upfront license fees received under collaboration
agreements depends upon the terms of the agreement.
The Company recognizes revenue from reimbursements earned in connection with research and
development collaboration agreements as related research and development costs are incurred, and
contractual services are performed. The Company includes amounts contractually owed to it under
these research and development collaboration agreements, including any earned but unbilled
receivables, in receivables in its balance sheets. The Companys principal costs under these
agreements are generally for its personnel and related expenses of conducting research and
development, as well as for research and development performed by outside contractors or
consultants or related research and development materials provided by third parties or for clinical
trials it conducts on behalf of a collaborator.
For payments that are contingent upon milestone events or achieving a specific result from the
research and development efforts the Company recognizes these milestone payments as revenue in
their entirety upon achieving the related milestone provided the milestone meets the criteria
specified below. Milestones typically consist of significant events in the development life cycle
of the related technology, such as initiating clinical trials, filing for approval with regulatory
agencies, and obtaining approvals from regulatory agencies. The Company recognizes revenue from
milestone payments received under collaboration agreements in their entirety upon achieving the
related milestone, provided that the milestone event is substantive, its achievability was not
reasonably assured at the inception of the agreement, the amount attributed to the milestone is
reasonable in relation to the Companys performance and to the amounts attributed to the other
deliverables in the arrangement and the Company has no further performance obligations relating to
the milestone event. In the event that the agreement provides for payment to be made subsequent to
the Companys standard payment terms, the Company recognizes revenue when payment becomes due.
Amounts received prior to satisfying the above revenue recognition criteria are recorded as
deferred revenue in the Companys balance sheets. The Company classifies amounts that it expects to
recognize in the next twelve months as short-term deferred revenue. The Company classifies amounts
that it does not expect to recognize within the next twelve months as long-term deferred revenue.
Although the Company follows detailed guidelines in measuring revenue, certain judgments
affect the application of its revenue policy. For example, in connection with its existing
collaboration agreements, any deferred revenue the Company has recorded on its balance sheet is
classified as short-term or long-term deferred revenue based on its best estimate of when such
amounts will be recognized. However, these estimates are based on the Companys collaboration
agreements and its then current operating plan and, if either should change, the Company may
recognize a different amount of deferred revenue over the subsequent twelve-month period.
The Companys estimate of deferred revenue also reflects managements estimate of the periods
of its involvement in its collaborations and the estimated periods over which its performance
obligations will be completed. In some instances, the timing of satisfying these obligations can be
difficult to estimate. Accordingly, the Companys estimates may change in subsequent periods. Such
changes to estimates would result in a change in
9
Table of Contents
revenue recognition amounts. If these estimates
and judgments change over the course of these agreements, it may affect the timing and amount of
revenue that the Company recognizes and records in subsequent periods.
Additional information on the Companys collaborative arrangements is included in Notes (9)
and (10).
(9) Collaboration and License Agreement with Merck KGaA
In December 2007, the Company entered into an exclusive, worldwide license agreement with
Merck KGaA to research, develop and commercialize products containing its TLR9 agonists for the
treatment of cancer, excluding cancer vaccines, which agreement became effective February 4, 2008.
Under the terms of the agreement, the Company granted Merck KGaA worldwide exclusive rights to its
lead TLR9 agonists, IMO-2055 and IMO-2125, and to a specified number of novel, follow-on TLR9
agonists to be identified by Merck KGaA and the Company under a research collaboration, for use in
the treatment, cure and/or delay of the onset or progression of cancer in humans. Under the terms
of the agreement: Merck KGaA paid the Company in February 2008 a $40.0 million upfront license fee
in Euros of which $39.7 million was received due to foreign currency exchange rates in effect at
that time; Merck KGaA agreed to reimburse future development costs for certain of the Companys
IMO-2055 clinical trials for the period in which the Company continued to conduct the trials on
behalf of Merck KGaA; Merck KGaA agreed to pay up to 264 million in development, regulatory
approval, and commercial success milestone payments if products containing the Companys TLR9
agonist compounds are successfully developed and marketed for treatment, cure and/or delay of the
onset or progression of cancer in humans; and Merck KGaA agreed to pay mid single-digit to low
double digit royalties on net sales of products containing the Companys TLR9 agonists that are
marketed. Merck KGaA refers to IMO-2055 as EMD 1201081. In February 2009, the agreement was amended
so that the Company could initiate and conduct on behalf of Merck KGaA additional clinical trials
of EMD 1201081 until such time as Merck KGaA had filed an Investigational New Drug (IND)
application with the U.S. Food and Drug Administration (FDA) and assumed sponsorship of these
trials. Under the amendment, Merck KGaA agreed to reimburse the Company for costs associated with
any additional trials that the Company initiated and conducted. Merck KGaA filed an IND and, as of
March 2010, Merck KGaA assumed sponsorship of all ongoing clinical trials of EMD 1201081, for the
treatment of cancer, and has assumed responsibility for all further clinical development of EMD
1201081 in the treatment of cancer, excluding vaccines.
The Company recognized the $40.0 million upfront payment as revenue over the twenty-eight
month term that ended in June 2010, which was the Companys period of continuing involvement under
the research collaboration. The Company has recognized a total of $12.1 million of milestone
revenue related to the initiation of clinical trials of EMD 1201081.
(10) Collaboration and License Agreement with Merck Sharp & Dohme Corp.
In December 2006, the Company entered into an exclusive, worldwide license and research
collaboration agreement with Merck to research, develop, and commercialize vaccine products
containing the Companys TLR7, 8, and 9 agonists in the fields of cancer, infectious diseases, and
Alzheimers disease. Under the terms of the agreement, the Company granted Merck exclusive rights
to a number of the Companys TLR7, 8, and 9 agonists for use in combination with Mercks
therapeutic and prophylactic vaccines under development in the fields of cancer, infectious
diseases, and Alzheimers disease. The Company also agreed with Merck to engage in a two-year
research collaboration to generate novel agonists targeting TLR7 and TLR8 incorporating both Merck
and Idera chemistry for use in vaccines in the defined fields, which collaboration was extended by
Merck for two additional one-year periods. Under the terms of the agreement: Merck paid the Company
a $20.0 million upfront license fee; Merck purchased $10.0 million of the Companys common stock at
$5.50 per share; and Merck agreed to fund the
research and development collaboration. Merck also agreed to pay the Company milestone
payments as follows: up to $165.0 million if vaccines containing the Companys TLR9 agonist
compounds are successfully developed and marketed in each of the oncology, infectious disease, and
Alzheimers disease fields; up to $260.0 million if vaccines containing the Companys TLR9 agonist
compounds are successfully developed and marketed for follow-on indications in the oncology field
and if vaccines containing the Companys TLR7 or TLR8 agonists are successfully developed and
marketed in each of the oncology, infectious disease, and Alzheimers disease fields;
10
Table of Contents
and if Merck
develops and commercializes additional vaccines using the Companys agonists, the Company would be
entitled to receive additional milestone payments. In addition, Merck agreed to pay the Company mid
to upper single-digit royalties on net product sales of vaccines using the Companys TLR agonist
technology that are developed and marketed.
The Company recognized the $20.0 million upfront payment as revenue over four years, including
the initial two-year research term and the additional two-year research term that ended in December
2010, which was the Companys period of continuing involvement under the research collaboration.
In December 2006, in connection with the execution of the license and collaboration agreement,
the Company entered into a stock purchase agreement with Merck. Pursuant to such stock purchase
agreement, the Company issued and sold to Merck 1,818,182 shares of the Companys common stock for
a price of $5.50 per share resulting in aggregate gross proceeds of $10.0 million.
In May 2008, under the Companys collaboration with Merck, a preclinical milestone was
achieved with one of its novel TLR9 agonists used as an adjuvant in cancer vaccines. As a result,
the Company recognized $1.0 million of milestone revenue in 2008.
(11) Stock-Based Compensation
The Company recognizes all share-based payments to employees and directors in the financial
statements based on their fair values. The Company records compensation expense over an awards
requisite service period, or vesting period, based on the awards fair value at the date of grant.
The Companys policy is to charge the fair value of stock options as an expense on a straight-line
basis over the vesting period, which is generally four years for employees and three years for
directors. The Company included charges of $660,000 and $1,173,000 in its statements of operations
for the three months ended March 31, 2011 and 2010, respectively, representing the stock-based
compensation expense attributable to share-based payments made to employees and directors.
The fair value of each option award is estimated on the date of grant using the Black-Scholes
option-pricing model and expensed over the requisite service period on a straight-line basis. The
following assumptions apply to the options to purchase 39,500 shares of common stock granted to
employees and directors during the three months ended March 31, 2010:
Three Months Ended | ||||
March 31, 2010 | ||||
Average risk free interest rate |
2.7 | % | ||
Expected dividend yield |
| |||
Expected lives (years) |
5.3 | |||
Expected volatility |
67.0 | % | ||
Weighted average grant date fair value of options granted during the period (per
share) |
$3.08 | |||
Weighted average exercise price of options granted during the period (per share) |
$5.23 |
The Company did not grant any stock options during the three months ended March 31, 2011.
During the first quarter of 2010, the Company adopted a policy with respect to the treatment
of stock options in the event of a non-employee director retirement which resulted in the
modification of stock options by accelerating the vesting of nonvested stock options held by, and
by extending the post-retirement period during which stock options may be exercised by, those
directors whose retirement would qualify under the terms of the policy. The stock option
modifications increased the fair value of those options by $85,000 when modified, of which $2,000
and $58,000 was expensed during the three months ended March 31, 2011 and 2010, respectively.
As a result of the stock option modifications, the Company recognized $290,000 more of
stock-based compensation expense during the three months ended March 31, 2010 than it would have
recognized if the stock options had not been modified. Of that amount, $58,000 was attributable to
the increase in fair value of the modified options and $232,000 was attributable to the accelerated
recognition of the original fair value of options held by
11
Table of Contents
directors who were or would become
eligible for retirement prior to the completion of the option vesting period, which amounts would
otherwise have been expensed over the vesting period on a straight line basis. As a result of the
stock option modifications, the Company did not recognize $28,000 of stock-based compensation
expense during the three months ended March 31, 2011 that it otherwise would have recognized if the
stock options had not been modified, which amount consisted of $30,000 that resulted from the
accelerated recognition of the original fair value of options held by directors who were or will
become eligible for retirement prior to the completion of the option vesting period, offset by a
$2,000 increase in expense attributable to the increase in fair value.
During prior periods, the Company awarded stock options to purchase shares of common stock to
persons who were neither employees nor directors. The fair value of the nonvested portion of the
non-employee, non-director options is remeasured each quarter. This remeasured fair value is
partially expensed each quarter based upon the percentage of the nonvested portion of the options
vesting period that has elapsed to date, less the amount expensed in prior periods. The Company
recorded approximately $6,000 and $14,000 as an expense for non-employee, non-director options in
the three months ended March 31, 2011 and 2010, respectively.
(12) Net Loss per Common Share
Basic and diluted net loss per common share is computed using the weighted average number of
shares of common stock outstanding during the period. For the three months ended March 31, 2011 and
2010, diluted net loss per share is the same as basic net loss per common share as the effects of
the Companys potential common stock equivalents are antidilutive. Total antidilutive securities
were 9,153,788 and 7,000,394 for the three months ended March 31, 2011 and 2010, respectively, and
consist of stock options and warrants. Net loss applicable to common stockholders is the same as
net loss for the three months ended March 31, 2011 and 2010.
(13) Stockholders Equity
During the three months ended March 31, 2011 and 2010, the Company issued 10,788 and 9,724
shares, respectively, of common stock in connection with stock option exercises and employee stock
purchases resulting in total proceeds to the Company of $23,000 and $39,000, respectively. During
the three months ended March 31, 2011, pursuant to its director compensation program, the Company
issued 4,404 shares of common stock to a director in lieu of cash fees of approximately $13,000.
(14) Related Party Transactions
The Company paid certain directors consulting fees of approximately $10,000 and $8,000 in the
three months ended March 31, 2011 and 2010, respectively.
12
Table of Contents
ITEM 2. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
GENERAL
We are engaged in the discovery and development of DNA- and RNA-based drug candidates targeted
to Toll-Like Receptors, or TLRs, to treat infectious diseases, autoimmune and inflammatory
diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants. Drug candidates are
compounds that we are developing and that have not been approved for any commercial use. TLRs are
specific receptors present in immune system cells that recognize the DNA or RNA of bacteria or
viruses and initiate an immune response. Relying on our expertise in DNA and RNA chemistry, we have
designed and created proprietary TLR agonists and antagonists to modulate immune responses. A TLR
agonist is a compound that stimulates an immune response through the targeted TLR. A TLR antagonist
is a compound that blocks activation of an immune response through the targeted TLR.
Our business strategy is to advance applications of our TLR-targeted drug candidates in
multiple disease areas simultaneously. We are advancing some of these applications through internal
programs, and we seek to advance other applications through collaborative alliances with
pharmaceutical companies. Collaborators provide the necessary resources and drug development
experience to advance our compounds in their programs. Upfront payments and milestone payments
received from collaborations help to provide us with the financial resources for our internal
research and development programs.
Our internal programs are focused on developing TLR-targeted drug candidates for the potential
treatment of infectious diseases, autoimmune and inflammatory diseases, cancer, and respiratory
diseases, and for use as vaccine adjuvants. We have completed two Phase 1 clinical trials of
IMO-2125, a TLR9 agonist, in patients with chronic hepatitis C virus, or HCV, infection. We have
chosen to delay initiation of our planned 12-week Phase 2 randomized clinical trial of IMO-2125
plus ribavirin in treatment-naïve HCV patients based on preliminary observations from a 26-week
chronic nonclinical toxicology study of IMO-2125 in rodents. We plan to determine our path forward
after full evaluation of the data from the chronic nonclinical toxicology study of IMO-2125 in
rodents, as well as from a chronic nonclinical toxicology study of IMO-2125 in nonhuman primates.
We expect these data to be available in the second half of 2011. We have completed two Phase 1
clinical trials of IMO-3100, an antagonist of TLR7 and TLR9, in healthy subjects. We expect to
complete ongoing nonclinical studies of IMO-3100 during the second quarter of 2011 and to submit to
the FDA a protocol for a Phase 2 clinical trial of IMO-3100 in a selected autoimmune disease
indication during the third quarter of 2011, which trial we expect to initiate by the end of 2011.
We are also advancing our gene silencing oligonucleotide, or GSO, technology for potential
application as research reagents and as therapeutic agents.
In addition to our internal programs, we currently are collaborating with two pharmaceutical
companies to advance other applications of our TLR-targeted compounds. We are collaborating with
Merck KGaA for the use of TLR9 agonists in cancer treatment, excluding cancer vaccines. Merck KGaA
is conducting clinical trials of IMO-2055, which Merck KGaA refers to as EMD 1201081, in
combination with other cancer therapy agents in cancer indications including a Phase 2 clinical
trial in squamous cell carcinoma of the head and neck. We also are collaborating with Merck Sharpe
& Dohme Corp., or Merck, for the use of TLR7, TLR8, and TLR9 agonists as vaccine adjuvants in the
fields of cancer, infectious diseases, and Alzheimers disease. Merck KGaA and Merck are not
related.
At March 31, 2011, we had an accumulated deficit of $358,487,000. We expect to incur
substantial operating losses in future periods. We do not expect to
generate significant product revenue or royalties until we successfully complete development and obtain marketing approval for drug
candidates, either alone or in collaborations with third parties, which we expect will take a
number of years. In order to commercialize our drug candidates, we
need to complete clinical trials and to comply with comprehensive regulatory requirements. In 2011, we
expect that our research and development expenses will be lower than our research and development
expenses in 2010 reflecting the completion of multiple Phase 1 clinical trials in 2010 and our
clinical development plan for 2011.
13
Table of Contents
CRITICAL ACCOUNTING POLICIES AND ESTIMATES
This managements discussion and analysis of financial condition and results of operations is
based on our financial statements, which have been prepared in accordance with accounting
principles generally accepted in the United States. The preparation of these financial statements
requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and the disclosure of contingent assets and liabilities at the date of the
financial statements and the reported amounts of revenues and expenses during the reporting period.
On an ongoing basis, management evaluates its estimates and judgments, including those related to
revenue recognition and stock-based compensation. Management bases its estimates and judgments on
historical experience and on various other factors that are believed to be reasonable under the
circumstances, the results of which form the basis for making judgments about the carrying values
of assets and liabilities that are not readily apparent from other sources. Actual results may
differ from these estimates under different assumptions or conditions.
We regard an accounting estimate or assumption underlying our financial statements as a
critical accounting estimate where:
| the nature of the estimate or assumption is material due to the level of subjectivity and judgment necessary to account for highly uncertain matters or the susceptibility of such matters to change; and | ||
| the impact of the estimates and assumptions on financial condition or operating performance is material. |
Our significant accounting policies are described in Note 2 of the notes to our financial
statements in our Annual Report on Form 10-K for the year ended December 31, 2010. Not all of
these significant policies, however, fit the definition of critical accounting policies and
estimates. We believe that our accounting policies relating to revenue recognition and stock-based
compensation, as described under the caption Item 7. Managements Discussion and Analysis of
Financial Condition and Results of Operations Critical Accounting Policies and Estimates in our
Annual Report on Form 10-K for the year ended December 31, 2010, fit the description of critical
accounting estimates and judgments.
RESULTS OF OPERATIONS
Three Months Ended March 31, 2011 and 2010
Alliance Revenue
Our alliance revenues are comprised primarily of revenue earned under various collaboration
and licensing agreements which include license fees, research and development revenues including
reimbursement of internal and third-party expenses, milestones and patent-related reimbursements.
The following table is a summary of our alliance revenue earned under our collaboration and
licensing agreements:
Three Months Ended March 31, | Percentage | |||||||||||
(in thousands) | Increase | |||||||||||
2011 | 2010 | (Decrease) | ||||||||||
License fees |
$ | | $ | 5,553 | (100 | )% | ||||||
Research and development |
| 18 | (100 | )% | ||||||||
Other |
8 | 6 | 33 | % | ||||||||
Total alliance revenue |
$ | 8 | $ | 5,577 | (100 | )% | ||||||
License Fees. License fees primarily include license fee revenue recognized under our
collaborations with Merck KGaA and Merck. License fee revenue during the three months ended March
31, 2010 was comprised of amortization of the upfront license fee payments under these
collaborations. We recognized license fee revenue
14
Table of Contents
ratably over the expected period of our continuing involvement in the
collaborations, which has generally represented the estimated research period of the agreement.
We received a $40,000,000 upfront payment from Merck KGaA in Euros in February 2008 of which
we received $39,733,000 due to foreign currency exchange rates in effect at the time. We recognized
the $40,000,000 upfront payment as revenue over the twenty eight-month research term that ended in
June 2010. We received a $20,000,000 upfront payment from Merck in December 2006. We recognized the
$20,000,000 upfront payment as revenue over the two-year initial research term and the two-year
extension period that ended in December 2010. Since we completed the research portions of these
collaborations during 2010, all of the upfront license fee payments were fully amortized by
December 2010. Consequently, we did not recognize any license fee revenue under the Merck KGaA and
Merck collaborations during the three months ended March 31, 2011.
Research and Development Revenue. Research and development revenue was $18,000 in the three
months ended March 31, 2010 and consisted of reimbursement by Merck KGaA of costs associated with
clinical trials of IMO-2055. Merck KGaA assumed sponsorship of these trials by March 2010, and
consequently we did not recognize any research and development revenue in the three months ended
March 31, 2011. We do not expect to have research and development revenue in future
periods under our agreements with Merck KGaA and Merck.
Other Revenue. Other revenue consisted of reimbursement by licensees of costs associated with
patent maintenance.
Research and Development Expenses
Research and development expenses decreased by $33,000, or 1%, from $4,586,000 for the three
months ended March 31, 2010, to $4,553,000 for the three months ended March 31, 2011. In the
following table, research and development expense is set forth in the following four categories
which are discussed beneath the table:
Three Months Ended March 31, | Percentage | |||||||||||
(in thousands) | Increase | |||||||||||
2011 | 2010 | (Decrease) | ||||||||||
IMO-2125 External
Development Expense |
$ | 1,231 | $ | 881 | 40 | % | ||||||
IMO-3100 External
Development Expense |
254 | 891 | (71 | )% | ||||||||
Other Drug Development
Expense |
1,024 | 981 | 4 | % | ||||||||
Basic Discovery Expense |
2,044 | 1,833 | 12 | % | ||||||||
Total Research and
Development Expense |
$ | 4,553 | $ | 4,586 | (1 | )% | ||||||
IMO-2125 External Development Expenses. These expenses include external expenses that we
have incurred in connection with IMO-2125. These external expenses include payments to independent
contractors and vendors for drug development activities conducted after the initiation of IMO-2125
clinical development, but exclude internal costs such as payroll and overhead expenses. We
commenced clinical development of IMO-2125 in May 2007 and since then we have incurred
approximately $15,464,000 in external development expenses through March 31, 2011, including costs
associated with our clinical trials, manufacturing and process development activities related to
the production of IMO-2125, and additional nonclinical toxicology studies.
The increase in IMO-2125 expenses in the three months ended March 31, 2011 as compared to the
corresponding 2010 period was attributable to costs associated with preparation for the Phase 2
clinical trial of IMO-2125 we planned to initiate in the second quarter of 2011 and conduct of
additional nonclinical toxicology studies of IMO-2125. These increases were partially offset by
decreases in costs associated with the two Phase 1 clinical trials for which we completed all
patient activities prior to the end of 2010 and manufacturing costs incurred during the first
quarter of 2010 but not in the corresponding 2011 period.
15
Table of Contents
In May 2007, we submitted an Investigational New Drug, or IND, application for IMO-2125 to the
United States Food and Drug Administration, or FDA. In September 2007, we initiated a Phase 1
clinical trial of IMO-2125 in patients with genotype 1 chronic HCV infection who had no response to
a prior regimen of the current standard of care therapy specified by the protocol as patients who
failed to achieve a 2 log10 reduction in HCV viral load after at least 12 weeks of
treatment with the current standard of care therapy. HCV viral load refers to the concentration of
virus in the blood. A log10 reduction means a decrease in virus concentration to 10% of
the original concentration. A 2 log10 reduction means a decrease to 1% of the original
concentration. We refer to these patients as null-responder HCV patients. The clinical trial was
conducted at a total of eleven sites in the United States with a total of 58 patients. In the
trial, we enrolled cohorts of ten patients at escalating IMO-2125 dose levels of 0.04 mg/kg/week,
0.08 mg/kg/week, 0.16 mg/kg/week, 0.32 mg/kg/week, and 0.48 mg/kg/week. Of the ten patients in a
cohort, eight were randomized to receive IMO-2125 treatment and two were randomized to receive
placebo treatment. Patients received a single dose of IMO-2125 or placebo once per week by
subcutaneous injection for four weeks. Based on interim results from these cohorts, we enrolled
seven additional patients who received 0.16 mg/kg of IMO-2125 twice weekly for four weeks. The
primary objective of the trial was to assess the safety of IMO-2125 at each dose level. We also
evaluated the effects of IMO-2125 on HCV RNA levels and on immune system activation in this trial.
We presented results from the Phase 1 clinical trial of IMO-2125 in null-responder HCV patients at
scientific meetings in April 2010 and in October 2010.
We also conducted a Phase 1 clinical trial of IMO-2125 in combination with ribavirin, an
antiviral medication approved for use in combination with interferon-alpha in the treatment of HCV
infection, in treatment-naïve patients with genotype 1 chronic HCV infection. We initiated the
trial in October 2009. In this clinical trial, a total of 63 patients received IMO-2125 or a
control article by subcutaneous injection once per week for four weeks at escalating dose levels in
combination with daily oral administration of standard doses of ribavirin. Fifteen patients were
enrolled in the first cohort, with 12 randomized to receive IMO-2125 at 0.08 mg/kg/week and
ribavirin and three randomized to receive placebo and ribavirin as the control. Eighteen patients
were enrolled in the second cohort, with 12 randomized to receive IMO-2125 at 0.16 mg/kg/week and
ribavirin and six randomized to receive pegylated recombinant alfa-2a interferon and ribavirin as
the control. The third cohort enrolled 30 patients randomized 12:12:6 to receive IMO-2125 at 0.32
mg/kg/week, IMO-2125 at 0.16 mg/kg twice per week, or pegylated recombinant alfa-2a interferon,
respectively, all with ribavirin. The primary objective of the trial was to assess the safety and
tolerability of IMO-2125 in combination with ribavirin. In addition, we monitored the effect of
treatment on HCV RNA levels. The clinical trial was conducted at sites in France, Russia, and
Hungary. In December 2010, we announced preliminary data from the Phase 1 clinical trial of
IMO-2125 in treatment-naïve HCV patients, and in April 2011 we presented results at the
46th Annual Meeting of the European Association of the Study of the Liver.
In April 2011, we chose to delay initiation of our planned 12-week Phase 2 randomized clinical
trial of IMO-2125 plus ribavirin in treatment-naïve, genotype 1 HCV patients based on preliminary
observations in a 26-week chronic nonclinical toxicology study of IMO-2125 in rodents. We are
completing a 26-week chronic nonclinical toxicology study of IMO-2125 in rodents and a 39-week
chronic nonclinical toxicology study of IMO-2125 in non-human
primates. Preliminary histology analysis from the rodent study showed instances of atypical lymphocytic proliferation. We
expect data from the non-human primate study and additional histology data from the rodent study
during the second half of 2011. We plan to determine our path forward after we have fully
evaluated the data from our chronic nonclinical toxicology studies of IMO-2125.
IMO-3100 External Development Expenses. These expenses include external expenses that we have
incurred in connection with IMO-3100 since November 2009, when we commenced clinical development of
IMO-3100. These external expenses include payments to independent contractors and vendors for drug
development activities conducted after the initiation of IMO-3100 clinical development but exclude
internal costs such as payroll and overhead expenses. Since November 2009, we have incurred
approximately $6,036,000 in external development expenses through March 31, 2011, including costs
associated with our clinical trials, manufacturing and process development activities related to
the production of IMO-3100, and additional nonclinical toxicology studies.
16
Table of Contents
The decrease in IMO-3100 expenses in the three months ended March 31, 2011 as compared to the
corresponding 2010 period was primarily attributable to completion of all patient activities of the
two Phase 1 clinical trials during 2010 and lower costs associated with nonclinical toxicology
studies conducted during the three months ended March 31, 2011.
In November 2009, we submitted to the FDA an IND application for the clinical evaluation of
IMO-3100 in autoimmune diseases. In January 2010, we initiated a Phase 1 clinical trial of IMO-3100
in healthy subjects. In this single-dose, dose escalation Phase 1 trial, IMO-3100 was administered
by subcutaneous injection at dose levels of 0.04, 0.08, 0.16, 0.32, and 0.64 mg/kg to a total of 36
subjects. At each dose level, six subjects received IMO-3100. An additional six subjects received
placebo treatment. The primary objective of the trial was to evaluate the safety and tolerability
of IMO-3100. Secondary objectives were to characterize the pharmacokinetic profile of IMO-3100 and
to assess the pharmacodynamic mechanism of action of IMO-3100. The pharmacodynamic mechanism of
action is how IMO-3100 engages the immune system in the targeted manner, which we assessed through
measurement of the inhibition of TLR7 and TLR9-mediated cytokine induction in peripheral blood
mononuculear cells, or PBMCs. The trial was conducted at a single U.S. site. In October 2010 we
announced results from the single-dose Phase 1 clinical trial of IMO-3100. IMO-3100 was well
tolerated at all dose levels in the trial.
We have also conducted a four-week multiple-dose Phase 1 clinical trial of IMO-3100 in healthy
subjects that we initiated in July 2010 and completed in the third quarter of 2010. We presented
results of the multi-dose Phase 1 clinical trial at a scientific meeting in April 2011.
We intend for the next step in the clinical development of IMO-3100 to be a Phase 2 clinical
trial in a selected autoimmune disease indication, which we expect to initiate by the end of 2011.
We are currently conducting nonclinical studies of IMO-3100, in light of some reversible immune
responses that were observed in the 13-week nonclinical toxicology studies we had conducted to
support the initiation of Phase 2 clinical trials and that were inconsistent with observations in
our other nonclinical studies of IMO-3100. We expect to complete these nonclinical studies during
the second quarter of 2011 and submit to the FDA the results of these nonclinical studies and a
protocol for the Phase 2 clinical trial of IMO-3100 in the selected autoimmune disease indication
during the third quarter of 2011.
Other Drug Development Expenses. These expenses include external expenses associated with
preclinical development of identified compounds in anticipation of advancing these compounds into
clinical development. In addition, these expenses include internal costs, such as payroll and
overhead expenses, associated with preclinical development and products in clinical development.
The external expenses associated with preclinical compounds include payments to contract vendors
for manufacturing and the related stability studies, preclinical studies, including animal
toxicology and pharmacology studies, and professional fees. Expenses associated with products in
clinical development include costs associated with our Hepatitis C Clinical Advisory Board and our
Autoimmune Disease Scientific Advisory Board.
Other drug development expenses increased by $43,000, or 4%, in the three months ended March
31, 2011, as compared to the corresponding 2010 period. The increase in the three months ended
March 31, 2011 compared to the corresponding 2010 period was primarily due to higher consulting
costs partially offset by lower employee expenses in the 2011 period.
Basic Discovery Expenses. These expenses include our internal and external expenses relating
to the discovery of our TLR-targeted programs, including agonists and antagonists of TLRs 3, 7, 8
and 9, and TLR antisense, and GSOs. These expenses reflect payments for laboratory supplies,
external research, and professional fees, as well as payroll and overhead expenses. Basic discovery
expenses increased by $211,000, or 12%, in the three months ended March 31, 2011, as compared to
the corresponding 2010 period. The increase in basic discovery expenses in the three months ended
March 31, 2011, as compared to the corresponding 2010 period was mainly due to increases in the
cost of laboratory supplies, employee expenses and external nonclinical research costs.
We do not know if we will be successful in developing any drug candidate from our research and
development programs. At this time, without knowing the results of our ongoing clinical trials and
without an established plan for
17
Table of Contents
future clinical tests of drug candidates, we cannot reasonably estimate or know the nature,
timing, and costs of the efforts that will be necessary to complete the remainder of the
development of, or the period, if any, in which material net cash inflows may commence from, any
drug candidate from our research and development programs. Moreover, the clinical development of
any drug candidate from our research and development programs is subject to numerous risks and
uncertainties associated with the duration and cost of clinical trials, which vary significantly
over the life of a project as a result of unanticipated events arising during clinical development.
General and Administrative Expenses
General and administrative expenses decreased by $446,000 from $2,732,000 in the three months
ended March 31, 2010, to $2,286,000 in the three months ended March 31, 2011. General and
administrative expenses consist primarily of salary expense, stock compensation expense, consulting
fees and professional legal fees associated with our patent applications and maintenance, our
corporate regulatory filing requirements, our corporate legal matters, and our business development
initiatives.
The decrease in general and administrative expenses in the three months ended March 31, 2011,
compared to the three months ended March 31, 2010 was primarily due to a decrease in stock based
compensation, mainly due to costs associated with the modification of non-employee director stock
options in the three months ended March 31, 2010, and lower employee cash compensation expenses in
the corresponding 2011 period. The decrease in general and administrative expenses was partially
offset by an increase in legal costs associated with patent matters in the 2011 period.
Investment Income, net
Investment income, net was approximately the same in the three months ended March 31, 2011 as
it was in the corresponding 2010 period.
Foreign Currency Exchange Loss
Foreign currency exchange loss was $35,000 in the three months ended March 31, 2011 compared
to $228,000 in the corresponding 2010 period. Foreign currency exchange gains and losses result
from amounts received under our Merck KGaA collaboration agreement and payments under our clinical
trial agreements that are denominated in Euros.
In 2009, we earned a milestone under our Merck KGaA collaboration, for which we had a
$4,300,000 receivable at December 31, 2009. Merck KGaA paid us for this milestone in February 2010
and we received $4,074,000 based on foreign exchange rates in effect at the time of payment as a
result of the strengthening value of the U.S. dollar. Consequently, we had a foreign currency
exchange loss of $228,000 in the three months ended March 31, 2010
Net Loss
As a result of the factors discussed above, our net loss was $6,845,000 for the three months
ended March 31, 2011, compared to $1,943,000 for the three months ended March 31, 2010. Since
January 1, 2001, we have primarily been involved in the development of our TLR pipeline. From
January 1, 2001 through March 31, 2011, we incurred losses of $98,294,000. We also incurred net
losses of $260,193,000 prior to December 31, 2000 during which time we were primarily involved in
the development of non-TLR targeted antisense technology. Since our inception, we had an
accumulated deficit of $358,487,000 through March 31, 2011. We expect to continue to incur
substantial operating losses in the future.
18
Table of Contents
LIQUIDITY AND CAPITAL RESOURCES
Sources of Liquidity
We require cash to fund our operating expenses and to make capital expenditures. Historically,
we have funded our cash requirements primarily through the following:
| equity and debt financing; | ||
| license fees, research funding and milestone payments under collaborative and license agreements; | ||
| interest income; and | ||
| lease financings. |
In August 2010, we raised $15,103,000 in gross proceeds from a registered direct offering of
our common stock to institutional investors. In the offering, we sold 4,071,005 shares of common
stock and warrants to purchase 1,628,402 shares of common stock. The common stock and the warrants
were sold in units at a price of $3.71 per unit, with each unit consisting of one share of common
stock and warrants to purchase 0.40 shares of common stock. The warrants to purchase common stock
have an exercise price of $3.71 per share, are exercisable immediately, and will expire if not
exercised on or prior to August 5, 2015. The net proceeds to us from the offering, excluding the
proceeds of any future exercise of the warrants, were approximately $14,089,000.
In addition to the warrants mentioned above, as of March 31, 2011, warrants to purchase
1,704,545 shares of our common stock at an exercise price of $5.20 per share and warrants to
purchase 761,718 shares of our common stock at an exercise price of $5.92 per share were
outstanding. These warrants were issued in March 2006 and expire on September 24, 2011.
Under the terms of our collaboration with Merck KGaA, in February 2008 Merck KGaA paid us a
$40,000,000 upfront license fee in Euros of which we received $39,733,000 due to foreign currency
exchange rates. Since entering this agreement, we have received approximately $12,110,000 in
milestone payments and have been reimbursed $4,542,000 for expenses related to the development of
EMD 1201081.
In December 2006, we entered into an exclusive license and research collaboration agreement
with Merck to research, develop and commercialize vaccine products containing our TLR7, 8 and 9
agonists in the fields of cancer, infectious diseases and Alzheimers disease. Under the terms of
the agreement, Merck paid us a $20,000,000 license fee in December 2006. In addition, in connection
with the execution of the license and collaboration agreement, we issued and sold to Merck
1,818,182 shares of our common stock for a price of $5.50 per share resulting in an aggregate
purchase price of $10,000,000. Since entering this agreement, we have received $1.0 million in
milestone payments and $3.4 million in research and development payments.
Cash Flows
As of March 31, 2011, we had approximately $28,346,000 in cash and cash equivalents and
investments, a net decrease of approximately $6,297,000 from December 31, 2010. Net cash used in
operating activities totaled $6,260,000 during the three months ended March 31, 2011. The
$6,260,000 reflects our $6,845,000 net loss for the period, as adjusted for non-cash expenses,
including stock-based compensation, depreciation and amortization. It also reflects changes in our accounts receivable, prepaid expenses and accounts payable,
accrued expenses and other liabilities.
The net cash provided by investing activities during the three months ended March 31, 2011 of
$10,342,000 reflects the maturity of $11,385,000 in available-for-sale securities offset by the
purchase of approximately $1,025,000 of securities and $18,000 of laboratory equipment and
leasehold improvements during the period.
19
Table of Contents
The $19,000 net cash provided by financing activities during the three months ended March 31,
2011 reflects the proceeds of $23,000 received from employee stock purchases, offset, in part, by
payments on our capital leases.
As of March 31, 2010, we had approximately $37,646,000 in cash and cash equivalents and
investments, a net decrease of approximately $2,561,000 from December 31, 2009. Net cash used in
operating activities totaled $2,503,000 during the three months ended March 31, 2010, reflecting
our $1,943,000 net loss for the period, as adjusted for non-cash revenue and expenses, including
the reduction in deferred revenue associated with the recognition of deferred revenue under our
collaboration agreements, stock-based compensation, depreciation and amortization. It also reflects
changes in our accounts receivable, prepaid expenses and accounts payable, accrued expenses and
other liabilities.
The net cash used in investing activities during the three months ended March 31, 2010 of
$8,166,000 reflects our purchase of $8,106,000 in available-for-sale securities in the three months
ended March 31, 2010 and our purchase of $60,000 of laboratory and computer equipment in the
three-month period.
The net cash provided by financing activities during the three months ended March 31, 2010 of
$34,000 reflects proceeds of $39,000 received from the exercise of common stock options and
employee stock purchases during the three-month period offset, in part, by payments on our capital
leases.
Funding Requirements
We have incurred operating losses in all fiscal years except 2002, 2008, and 2009, and we had
an accumulated deficit of $358,487,000 at March 31, 2011. We expect to incur substantial operating
losses in future periods. These losses, among other things, have had and will continue to have an
adverse effect on our stockholders equity, total assets and working capital.
We have received no revenues from the sale of drugs. To date, almost all of our revenues have
been from collaboration and license agreements. We have devoted substantially all of our efforts to
research and development, including clinical trials, and we have not completed development of any
drugs. Because of the numerous risks and uncertainties associated with developing drugs, we are
unable to predict the extent of any future losses, whether or when any of our products will become
commercially available or when we will become profitable, if at all.
We do not expect to generate significant additional funds internally until we successfully
complete development and obtain marketing approval for products, either alone or in collaboration
with third parties, which we expect will take a number of years. In addition, we have no committed
external sources of funds.
We had cash, cash equivalents, and investments of $28,346,000 at March 31, 2011. We believe
that our existing cash, cash equivalents, and investments will be sufficient to fund our operations
at least through March 31, 2012 based on our current operating
plan. We expect to need to raise
additional funds to operate our business beyond March 31, 2012. We may seek additional capital due
to favorable market conditions or strategic considerations even if we believe we have sufficient
funds for our current or future operating plans.
We expect to seek additional funding through collaborations, the sale or license of assets or
financings of equity or debt securities. We believe that the key factors that will affect our
ability to obtain additional funding are:
| the success of our clinical and preclinical development programs; | ||
| the success of our existing strategic collaborations with Merck KGaA and Merck; | ||
| the cost, timing, and outcome of regulatory reviews; | ||
| competitive and potentially competitive products and technologies and investors receptivity to our drug candidates and the technology underlying them in light of competitive products and technologies; |
20
Table of Contents
| the receptivity of the capital markets to financings by biotechnology companies generally and companies with drug candidates and technologies such as ours specifically; and | ||
| our ability to enter into new strategic collaborations with biotechnology and pharmaceutical companies and the success of such collaborations. |
In addition, increases in expenses or delays in clinical development may adversely impact our
cash position and require additional funds or further cost reductions. Additional financing may not
be available to us when we need it or may not be available to us on favorable terms. We could be
required to seek funds through collaborative alliances or others that may require us to relinquish
rights to some of our technologies, drug candidates or drugs that we would otherwise pursue on our
own. In addition, if we raise additional funds by issuing equity securities, our then existing
stockholders will experience dilution. Debt financing, if available, may involve agreements that
include covenants limiting or restricting our ability to take specific actions, such as incurring
additional debt, making capital expenditures or declaring dividends, and are likely to include
rights that are senior to the holders of our common stock. Any additional debt financing or equity
that we raise may contain terms, such as liquidation and other preferences, or liens or other
restrictions on our assets, which are not favorable to us or our stockholders. The terms of any
financing may adversely affect the holdings or the rights of existing stockholders. If we are
unable to obtain adequate funding on a timely basis or at all, we may be required to significantly
curtail one or more of our discovery or development programs and possibly relinquish rights to
portions of our technology or products.
Contractual Obligations
During the three months ended March 31, 2011, there were no material changes outside the
ordinary course of our business to our contractual obligations as disclosed in our Annual Report of
Form 10-K for the year ended December 31, 2010.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Foreign currency exchange gains and losses may result from amounts received under our Merck
KGaA collaboration agreement and payments under our clinical trial agreements that are denominated
in Euros. As of March 31, 2011, we had net accrued obligations of 0.5 million, or $0.7 million.
All other assets and liabilities are in U.S. dollars, which is our functional currency.
We maintain investments in accordance with our investment policy. The primary objectives of
our investment activities are to preserve principal, maintain proper liquidity to meet operating
needs and maximize yields. Although our investments are subject to credit risk, our investment
policy specifies credit quality standards for our investments and limits the amount of credit
exposure from any single issue, issuer or type of investment. We regularly review our investment
holdings in light of the then current economic environment. We do not own auction rate securities
or derivative financial investment instruments in our investment portfolio.
Based on a hypothetical ten percent adverse movement in interest rates, the potential losses
in future earnings, fair value of risk sensitive financial instruments, and cash flows are
immaterial, although the actual effects may differ materially from the hypothetical analysis.
ITEM 4. CONTROLS AND PROCEDURES
(a) Evaluation of Disclosure Controls and Procedures. Our management, with the participation
of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our
disclosure controls and procedures as of the period covered by this report. The term disclosure
controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means
controls and other procedures of a company that are designed to ensure that information required to
be disclosed by a company in the reports that it files or submits
21
Table of Contents
under the Exchange Act is recorded, processed, summarized, and reported, within the time periods
specified in the SECs rules and forms. Disclosure controls and procedures include, without
limitation, controls and procedures designed to ensure that information required to be disclosed by
a company in the reports that it files or submits under the Exchange Act is accumulated and
communicated to the companys management, including its principal executive and principal financial
officers, as appropriate to allow timely decisions regarding required disclosure. Management
recognizes that any controls and procedures, no matter how well designed and operated, can provide
only reasonable assurance of achieving their objectives and management necessarily applies its
judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on
the evaluation of our disclosure controls and procedures as of March 31, 2011, our Chief Executive
Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and
procedures were effective at the reasonable assurance level.
(b) Changes in Internal Controls. No change in our internal control over financial reporting
(as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act) occurred during the
fiscal quarter ended March 31, 2011 that has materially affected, or is reasonably likely to
materially affect, our internal control over financial reporting.
22
Table of Contents
PART II OTHER INFORMATION
Item 1A. Risk Factors.
RISK FACTORS
Investing in our common stock involves a high degree of risk. You should carefully consider
the risks and uncertainties described below in addition to the other information included or
incorporated by reference in this Quarterly Report on Form 10-Q before purchasing our common stock.
If any of the following risks actually occurs, our business, financial condition or results of
operations would likely suffer, possibly materially. In that case, the trading price of our common
stock could fall, and you may lose all or part of the money you paid to buy our common stock.
Risks Relating to Our Financial Results and Need for Financing
We have incurred substantial losses and expect to continue to incur losses. We will not be
successful unless we reverse this trend.
We have incurred losses in every year since our inception, except for 2002, 2008, and 2009
when our recognition of revenues under license and collaboration agreements resulted in our
reporting net income for those years. As of March 31, 2011, we had an accumulated deficit of $358.5
million. Since January 1, 2001, we have primarily been involved in the development of our TLR
pipeline. From January 1, 2001 through March 31, 2011, we incurred losses of $98.3 million. We
incurred losses of $260.2 million prior to December 31, 2000 during which time we were primarily
involved in the development of non-TLR targeted antisense technology. These losses, among other
things, have had and will continue to have an adverse effect on our stockholders equity, total
assets, and working capital.
We have never had any products of our own available for commercial sale and have received no
revenues from the sale of drugs. To date, almost all of our revenues have been from collaborative
and license agreements. We have devoted substantially all of our efforts to research and
development, including clinical trials, and we have not completed development of any drug
candidates. Because of the numerous risks and uncertainties associated with developing drugs, we
are unable to predict the extent of any future losses, whether or when any of our drug candidates
will become commercially available, or when we will become profitable, if at all. We expect to
incur substantial operating losses in future periods.
We will need additional financing, which may be difficult to obtain. Our failure to obtain
necessary financing or doing so on unattractive terms could adversely affect our research and
development programs and other operations.
We will require substantial funds to conduct research and development, including preclinical
testing and clinical trials of our drug candidates. We will also require substantial funds to
conduct regulatory activities and to establish commercial manufacturing, marketing, and sales
capabilities. We had cash, cash equivalents, and investments of $28.3 million at March 31, 2011. We
believe that our existing cash, cash equivalents, and investments will be sufficient to fund our
operations at least through March 31, 2012 based on our current
operating plan. We expect to need
to raise additional funds to operate our business beyond March 31, 2012.
We expect to seek additional funding through collaborations, the sale or license of assets, or
financings of equity or debt securities. We believe that the key factors that will affect our
ability to obtain additional funding are:
| the success of our clinical and preclinical development programs; | ||
| the success of our existing strategic collaborations with Merck KGaA and Merck; |
23
Table of Contents
| the cost, timing, and outcome of regulatory reviews; | ||
| competitive and potentially competitive products and technologies and investors receptivity to our drug candidates and the technology underlying them in light of competitive products and technologies; | ||
| the receptivity of the capital markets to financings by biotechnology companies generally and companies with drug candidates and technologies such as ours specifically; and | ||
| our ability to enter into additional strategic collaborations with biotechnology and pharmaceutical companies and the success of such collaborations. |
Additional financing may not be available to us when we need it or may not be available to us
on favorable terms. We could be required to seek funds through collaborative alliances or through
other means that may require us to relinquish rights to some of our technologies, drug candidates
or drugs that we would otherwise pursue on our own. In addition, if we raise additional funds by
issuing equity securities, our then existing stockholders will experience dilution. The terms of
any financing may adversely affect the holdings or the rights of existing stockholders. Debt
financing, if available, may involve agreements that include covenants limiting or restricting our
ability to take specific actions, such as incurring additional debt, making capital expenditures or
declaring dividends, and are likely to include rights that are senior to the holders of our common
stock. Any additional debt financing or equity that we raise may contain terms, such as liquidation
and other preferences, or liens or other restrictions on our assets, which are not favorable to us
or our stockholders. If we are unable to obtain adequate funding on a timely basis or at all, we
may be required to terminate, modify or delay preclinical or clinical trials of one or more of our
drug candidates, fail to establish or delay the establishment of manufacturing, sale or marketing
capabilities, curtail research and development programs for new drug candidates and/or possibly
relinquish rights to portions of our technology, drug candidates and/or products. For example, we
significantly curtailed expenditures on our research and development programs during 1999 and 2000
because we did not have sufficient funds available to advance these programs at planned levels.
Risks Relating to Our Business, Strategy and Industry
We are depending heavily on the success of IMO-2125, IMO-3100, and our collaborative alliances. If
we or our collaborators are unable to successfully develop and commercialize our drug candidates,
or experience significant delays in doing so, our business will be materially harmed.
We are investing a significant portion of our time and financial resources in the development
of our clinical stage lead drug candidates for infectious diseases, IMO-2125, and for autoimmune
and inflammatory diseases, IMO-3100. We anticipate that our ability to generate product revenues
will depend heavily on the successful development and commercialization of IMO-2125, IMO-3100 and
other drug candidates being developed by our collaborators, including IMO-2055. Our efforts, and
the efforts of our collaborators, to develop and commercialize these compounds are at an early
stage and are subject to many challenges. The ability to successfully develop and commercialize
these drug candidates will depend on several factors, including the following:
| the drug candidates demonstrating an acceptable safety profile in nonclinical toxicology studies and during clinical trials; | ||
| timely enrollment in clinical trials of IMO-2125, IMO-3100 and other drug candidates, which may be slower than anticipated, potentially resulting in significant delays; | ||
| satisfying conditions imposed on us and/or our collaborators by the FDA or equivalent foreign regulatory authorities regarding the scope or design of clinical trials; | ||
| the ability to demonstrate to the satisfaction of the FDA, or equivalent foreign regulatory authorities, the safety and efficacy of the drug candidates through current and future clinical trials; |
24
Table of Contents
| the ability to combine our drug candidates and the drug candidates being developed by our collaborators safely and successfully with other therapeutic agents; | ||
| timely receipt of necessary marketing approvals from the FDA and equivalent foreign regulatory authorities; | ||
| achieving and maintaining compliance with all regulatory requirements applicable to the products; | ||
| establishment of commercial manufacturing arrangements with third-party manufacturers; | ||
| the successful commercial launch of the drug candidates, assuming FDA approval is obtained, whether alone or in combination with other products; | ||
| acceptance of the products as safe and effective by patients, the medical community and third-party payors; | ||
| competition from other companies and their therapies; | ||
| changes in treatment regimes; | ||
| successful protection of our intellectual property rights from competing products in the United States and abroad; and | ||
| a continued acceptable safety and efficacy profile of the drug candidates following marketing approval. |
In April 2011, we chose to delay initiation of our planned 12-week Phase 2 randomized clinical
trial of IMO-2125 plus ribavirin in treatment-naïve, genotype 1 HCV patients based on preliminary
observations in a 26-week chronic nonclinical toxicology study of IMO-2125 in rodents. We are
completing a chronic nonclinical toxicology study of IMO-2125 in rodents and a chronic nonclinical
toxicology study of IMO-2125 in non-human primates. Preliminary
histology analysis from
the rodent study showed instances of atypical lymphocytic proliferation. We expect data from the
non-human primate study and additional histology data from the rodent study during the second half
of 2011. We plan to determine our path forward after we have fully evaluated the data from our
chronic nonclinical toxicology studies of IMO-2125. However, such data could negatively impact our
ability or plans to proceed with the development and commercialization of IMO-2125.
If we or our collaborators are not successful in developing and commercializing IMO-2055,
IMO-2125, IMO-3100 or other drug candidates, or are significantly delayed in doing so, our business
will be materially harmed.
If our clinical trials are unsuccessful, or if they are delayed or terminated, we may not be able
to develop and commercialize our products.
In order to obtain regulatory approvals for the commercial sale of our products, we are
required to complete extensive clinical trials in humans to demonstrate the safety and efficacy of
our drug candidates. Clinical trials are lengthy, complex, and expensive processes with uncertain
results. We may not be able to complete any clinical trial of a potential product within any
specified time period. Moreover, clinical trials may not show our potential products to be both
safe and efficacious. The FDA or other equivalent foreign regulatory agencies may not allow us to
complete these trials or commence and complete any other clinical trials.
The results from preclinical testing of a drug candidate that is under development may not be
predictive of results that will be obtained in human clinical trials. In addition, the results of
early human clinical trials may not be predictive of results that will be obtained in larger scale,
advanced stage clinical trials. Furthermore, interim results of a clinical trial do not necessarily
predict final results, and failure of any of our clinical trials can occur at any stage of testing. Companies in the biotechnology and pharmaceutical industries, including companies
with greater experience in preclinical testing and clinical trials than we have, have suffered
significant setbacks in clinical trials, even after demonstrating promising results in earlier
trials.
25
Table of Contents
Moreover, companies developing drugs targeted to TLRs have experienced setbacks in clinical
trials. For example in 2007, Coley Pharmaceutical Group, which since has been acquired by Pfizer,
Inc., discontinued four clinical trials for PF-3512676, its investigational TLR9 agonist compound,
in combination with cytotoxic chemotherapy in cancer, and suspended its development of a TLR9
agonist, Actilon®, for HCV infection. In July 2007, Anadys Pharmaceuticals, Inc. and its
partner Novartis announced that they had decided to discontinue the development of ANA975, the
investigational TLR7 agonist compound for HCV infection. Dynavax Technologies Corporation announced
in May 2008 discontinuation of the clinical development program for TOLAMBA®, which
comprises a TLR9 agonist covalently attached to a ragweed antigen. There are few data on the
long-term clinical safety of our lead compounds under conditions of prolonged use in humans, or on
any long-term consequences subsequent to human use. Effects seen in nonclinical studies, even if
not observed in clinical trials, may result in limitations or restrictions on our clinical trials.
We may experience numerous unforeseen events during, or as a result of, preclinical testing,
nonclinical testing or the clinical trial process that could delay or inhibit our ability to
receive regulatory approval or to commercialize our products. For example, we are conducting
additional nonclinical studies of IMO-3100 before we initiate a Phase 2 clinical trial, in light of
some reversible immune responses that were observed in our 13-week nonclinical toxicology studies
and that were inconsistent with our other nonclinical studies of IMO-3100. We chose to delay
initiation of our planned Phase 2 clinical trial of IMO-2125 based on preliminary observations from
a 26-week chronic nonclinical toxicology study of IMO-2125 in rodents. We plan to determine our
path forward after full evaluation of the data from chronic nonclinical toxicology studies, which
we expect to be available in the second half of 2011.
Other events that could delay or inhibit conduct of our clinical trials include:
| regulators or IRBs may not authorize us to commence a clinical trial or conduct a clinical trial at a prospective trial site; | ||
| nonclinical or clinical data may not be readily interpreted, which may lead to delays and/or misinterpretation; | ||
| our nonclinical tests, including toxicology studies, or clinical trials may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional nonclinical testing or clinical trials or we may abandon projects that we expect may not be promising; | ||
| the rate of enrollment or retention of patients in our clinical trials may be lower than we expect; | ||
| we might have to suspend or terminate our clinical trials if the participating subjects experience serious adverse events or undesirable side effects or are exposed to unacceptable health risks; | ||
| regulators or IRBs may hold, suspend or terminate clinical research for various reasons, including noncompliance with regulatory requirements, issues identified through inspections of manufacturing or clinical trial operations or clinical trial sites, or if, in their opinion, the participating subjects are being exposed to unacceptable health risks; | ||
| regulators may hold or suspend our clinical trials while collecting supplemental information on, or clarification of, our clinical trials or other clinical trials, including trials conducted in other countries or trials conducted by other companies; | ||
| we, along with our collaborators and subcontractors, may not employ, in any capacity, persons who have been debarred under the FDAs Application Integrity Policy, or similar policy under foreign regulatory authorities. Employment of such debarred persons, even if inadvertent, may result in delays in the FDAs or foreign equivalents review or approval of our products, or the rejection of data developed with the involvement of such person(s); | ||
| the cost of our clinical trials may be greater than we currently anticipate; and |
26
Table of Contents
| our products may not cause the desired effects or may cause undesirable side effects or our products may have other unexpected characteristics. |
The rate of completion of clinical trials is dependent in part upon the rate of enrollment of
patients. For example, in our Phase 1 clinical trial of IMO-2125 in patients with chronic HCV
infection who had not responded to the current standard of care therapy, completion of each cohort
took longer than anticipated due to enrollment procedures. Patient accrual is a function of many
factors, including:
| the size of the patient population; | ||
| the proximity of patients to clinical sites; | ||
| the eligibility criteria for the study; | ||
| the nature of the study, including the pattern of patient enrollment; | ||
| the existence of competitive clinical trials; and | ||
| the availability of alternative treatments. |
We do not know whether clinical trials will begin as planned, will need to be restructured or
will be completed on schedule, if at all. Significant clinical trial delays also could allow our
competitors to bring products to market before we do and impair our ability to commercialize our
products.
Delays in commencing clinical trials of potential products could increase our costs, delay any
potential revenues, and reduce the probability that a potential product will receive regulatory
approval.
Our drug candidates and our collaborators drug candidates will require preclinical and other
nonclinical testing and extensive clinical trials prior to submission of any regulatory application
for commercial sales. In conducting clinical trials, we cannot be certain that any planned clinical
trial will begin on time, if at all. Delays in commencing clinical trials of potential products
could increase our product development costs, delay any potential revenues, and reduce the
probability that a potential product will receive regulatory approval.
Commencing clinical trials may be delayed for a number of reasons, including delays in:
| manufacturing sufficient quantities of drug candidate that satisfy the required quality standards for use in clinical trials; | ||
| demonstrating sufficient safety to obtain regulatory approval for conducting a clinical trial; | ||
| reaching an agreement with any collaborators on all aspects of the clinical trial; | ||
| reaching agreement with contract research organizations, if any, and clinical trial sites on all aspects of the clinical trial; | ||
| resolving any objections from the FDA or any regulatory authority on an IND application or proposed clinical trial design; | ||
| obtaining IRB approval for conducting a clinical trial at a prospective site; and | ||
| enrolling patients in order to commence the clinical trial. |
27
Table of Contents
The technologies on which we rely are unproven and may not result in any approved and marketable
products.
Our technologies or therapeutic approaches are relatively new and unproven. We have focused
our efforts on the research and development of RNA- and DNA-based compounds targeted to TLRs.
Neither we nor any other company have obtained regulatory approval to market such compounds as
therapeutic drugs, and no such products currently are being marketed. It is unknown whether the
results of preclinical studies with TLR-targeted compounds will be indicative of results that may
be obtained in clinical trials, and results we have obtained in the initial small-scale clinical
trials we have conducted to date may not be predictive of results in subsequent large-scale
clinical trials. Further, the chemical and pharmacological properties of RNA- and DNA-based
compounds targeted to TLRs may not be fully recognized in preclinical studies and small-scale
clinical trials, and such compounds may interact with human biological systems in unforeseen,
ineffective or harmful ways that we have not yet identified. As a result of these factors, we may
never succeed in obtaining regulatory approval to market any product. Furthermore, the commercial
success of any of our products for which we may obtain marketing approval from the FDA or other
regulatory authorities will depend upon their acceptance by patients, the medical community, and
third-party payors as clinically useful, safe, and cost-effective. In addition, if products based
upon TLR technology being developed by our competitors have negative clinical trial results or
otherwise are viewed negatively, the perception of our TLR technology and market acceptance of our
products could be impacted negatively.
Our efforts to educate the medical community on our potentially unique approaches may require
greater resources than would be typically required for products based on conventional technologies
or therapeutic approaches. The safety, efficacy, convenience, and cost-effectiveness of our
products as compared to competitive products will also affect market acceptance.
We face substantial competition, which may result in others discovering, developing or
commercializing drugs before or more successfully than us.
We are developing our TLR-targeted drug candidates for use in the treatment of infectious
diseases, autoimmune and inflammatory diseases, respiratory diseases, and cancer, and as vaccine
adjuvants. We are also advancing our gene silencing oligonucleotide, or GSO, technology for
potential application as research reagents and as therapeutic agents. For all of the disease areas
in which we are developing potential therapies, there are many other companies, public and private,
that are actively engaged in discovering, developing, and commercializing products and technologies
that may compete with our technologies and drug candidates and technology, including TLR targeted
compounds as well as non-TLR targeted therapies.
We are developing IMO-2125 for use as an alternative to recombinant interferon in the
treatment of HCV. The current standard of care in the treatment of HCV consists of a single
recombinant interferon-alpha protein plus ribavarin. If we are able to commercialize IMO-2125 for
chronic HCV infection, we will face competition from the interferons currently marketed today and
advanced forms of recombinant interferons being developed, including those being developed by
Bristol-Myers Squibb Company and Biolex Therapeutics, Inc. In addition, to the extent that a
therapy is developed as an alternative to the current standard of care that does not include
recombinant interferon or any alternative to recombinant interferon, we may face competition from
those therapies as well, such as protease and polymerase inhibitors being developed by Merck,
Vertex Pharmaceuticals, Inc. and Pharmasset, Inc. We are also aware of numerous other compounds in
clinical trials that target chronic HCV infection through a number of different mechanisms of
action, and we believe that there are many additional potential HCV treatments in research or early
development. There are also a number of companies developing TLR-targeted compounds for chronic HCV
infection, including Dynavax Technologies Corporation, Anadys Pharmaceuticals, Inc., and Gilead
Sciences, Inc.
Our principal competitors developing TLR-targeted compounds for autoimmune and inflammatory
diseases include Dynavax Technologies Corporation, with its collaborator, GlaxoSmithKline plc and for
respiratory diseases include AstraZeneca Pharmaceuticals plc, Pfizer, Inc., in collaboration with
Sanofi-Aventis Groupe, Cytos Biotechnology AG, Dynavax Technologies Corporation in collaboration
with AstraZeneca Pharmaceuticals plc, and VentiRx Pharmaceuticals. For our partnered programs, our
principal competitors developing TLR-targeted compounds for cancer treatment include Pfizer, Inc.,
Anadys Pharmaceuticals, Inc. and VentiRx Pharmaceuticals.
28
Table of Contents
Mercks vaccines using our TLR7, 8 or 9 agonists as adjuvants may compete with vaccines being
developed or marketed by GlaxoSmithKline plc, Novartis, Dynavax Technologies Corporation,
VaxInnate, Inc., Intercell AG, Cytos Biotechnology AG, and Celldex Therapeutics, Inc.
Some of these potentially competitive products have been in development or commercialized for
years, in some cases by large, well established pharmaceutical companies. Many of the marketed
products have been accepted by the medical community, patients, and third-party payors. Our ability
to compete may be affected by the previous adoption of such products by the medical community,
patients, and third-party payors. Additionally, in some instances, insurers and other third-party
payors seek to encourage the use of generic products, which makes branded products, such as our
drug candidates, potentially less attractive, from a cost perspective, to buyers.
We recognize that other companies, including large pharmaceutical companies, may be developing
or have plans to develop products and technologies that may compete with ours. Many of our
competitors have substantially greater financial, technical, and human resources than we have. In
addition, many of our competitors have significantly greater experience than we have in undertaking
preclinical studies and human clinical trials of new pharmaceutical products, obtaining FDA and
other regulatory approvals of products for use in health care and manufacturing, and marketing and
selling approved products. Our competitors may discover, develop or commercialize products or other
novel technologies that are more effective, safer or less costly than any that we are developing.
Our competitors may also obtain FDA or other regulatory approval for their products more rapidly
than we may obtain approval for ours.
We anticipate that the competition with our products and technologies will be based on a
number of factors including product efficacy, safety, availability, and price. The timing of market
introduction of our products and competitive products will also affect competition among products.
We expect the relative speed with which we can develop products, complete the clinical trials, and
approval processes and supply commercial quantities of the products to the market to be important
competitive factors. Our competitive position will also depend upon our ability to attract and
retain qualified personnel, to obtain patent protection or otherwise develop proprietary products
or processes, and protect our intellectual property, and to secure sufficient capital resources for
the period between technological conception and commercial sales.
Competition for technical and management personnel is intense in our industry, and we may not be
able to sustain our operations or grow if we are unable to attract and retain key personnel.
Our success is highly dependent on the retention of principal members of our technical and
management staff, including Dr. Sudhir Agrawal. Dr. Agrawal serves as our Chairman of the Board of
Directors, President and Chief Executive Officer. Dr. Agrawal has made significant contributions to
the field of oligonucleotide-based drug candidates, and has led the discovery and development of
our compounds targeted to TLRs. He is named as an inventor on over 400 patents and patent
applications worldwide. Dr. Agrawal provides us with leadership for our management team and
research and development activities. The loss of Dr. Agrawals services would be detrimental to our
ongoing scientific progress and the execution of our business plan.
We are a party to an employment agreement with Dr. Agrawal that expires on October 19, 2013,
but automatically extends annually for an additional year. This agreement may be terminated by us
or Dr. Agrawal for any reason or no reason at any time upon notice to the other party. We do not
carry key man life insurance for Dr. Agrawal.
Furthermore, our future growth will require hiring a number of qualified technical and
management personnel. Accordingly, recruiting and retaining such personnel in the future will be
critical to our success. There is intense competition from other companies and research and
academic institutions for qualified personnel in the areas of our activities. If we are not able to
continue to attract and retain, on acceptable terms, the qualified personnel necessary for the
continued development of our business, we may not be able to sustain our operations or growth.
29
Table of Contents
Regulatory Risks
We may not be able to obtain marketing approval for products resulting from our development
efforts.
All of the drug candidates that we are developing, or may develop in the future, will require
additional research and development, extensive preclinical studies, nonclinical testing, clinical
trials, and regulatory approval prior to any commercial sales. This process is lengthy, often
taking a number of years, is uncertain, and is expensive. Since our inception, we have conducted
clinical trials of a number of compounds. Currently, we have two candidates, IMO-2125 and IMO-3100,
in clinical development. The FDA and other regulatory authorities may not approve any of our
potential products for any indication.
We may need to address a number of technological challenges in order to complete development
of our products. Moreover, these products may not be effective in treating any disease or may prove
to have undesirable or unintended side effects, unintended alteration of the immune system over
time, toxicities or other characteristics that may preclude our obtaining regulatory approval or
prevent or limit commercial use. If we do not obtain necessary regulatory approvals, our business
will be adversely affected.
We are subject to comprehensive regulatory requirements, which are costly and time consuming to
comply with; if we fail to comply with these requirements, we could be subject to adverse
consequences and penalties.
The testing, manufacturing, labeling, advertising, promotion, export, and marketing of our
products are subject to extensive regulation by governmental authorities in Europe, the United
States, and elsewhere throughout the world.
In general, submission of materials requesting permission to conduct clinical trials may not
result in authorization by the FDA or any equivalent foreign regulatory agency to commence clinical
trials. Further, permission to continue ongoing trials may be withdrawn by the FDA or other
regulatory agencies at any time after initiation, based on new information available after the
initial authorization to commence clinical trials or for other reasons. In addition, submission of
an application for marketing approval to the relevant regulatory agency following completion of
clinical trials may not result in the regulatory agency approving the application if applicable
regulatory criteria are not satisfied, and may result in the regulatory agency requiring additional
testing or information.
Even if we obtain regulatory approval for any of our product candidates, we will be subject to
ongoing FDA obligations and regulatory oversight. Any regulatory approval of a product may contain
limitations on the approved indicated uses for which the product may be marketed or requirements
for costly post-marketing testing and surveillance to monitor the safety or efficacy of the
product. Any product for which we obtain marketing approval, along with the facilities at which the
product is manufactured, any post-approval clinical data, and any advertising and promotional
activities for the product will be subject to continual review and periodic inspections by the FDA
and other regulatory agencies.
Both before and after approval is obtained, failure to comply with regulatory requirements, or
discovery of previously unknown problems with a product, including adverse events of unanticipated
severity or frequency, may result in:
| the regulatory agencys delay in approving, or refusal to approve, an application for marketing of a product or a supplement to an approved application; | ||
| restrictions on our products or the marketing or manufacturing of our products; | ||
| withdrawal of our products from the market; | ||
| warning letters; | ||
| voluntary or mandatory product recalls; |
30
Table of Contents
| fines; | ||
| suspension or withdrawal of regulatory approvals; | ||
| product seizure or detention; | ||
| refusal to permit the import or export of our products; | ||
| injunctions or the imposition of civil penalties; and | ||
| criminal penalties. |
We have only limited experience in regulatory affairs and our products are based on new
technologies; these factors may affect our ability or the time we require to obtain necessary
regulatory approvals.
We have only limited experience in filing the applications necessary to obtain regulatory
approvals. Moreover, the products that result from our research and development programs will
likely be based on new technologies and new therapeutic approaches that have not been extensively
tested in humans. The regulatory requirements governing these types of products may be more
rigorous than for conventional drugs. As a result, we may experience a longer regulatory process in
connection with obtaining regulatory approvals of any product that we develop.
Failure to obtain regulatory approval in jurisdictions outside the United States will prevent us
from marketing our products abroad.
We intend to market our products, if approved, in markets outside the United States, which
will require separate regulatory approvals and compliance with numerous and varying regulatory
requirements. The approval procedures vary among such markets and may involve requirements for
additional testing, and the time required to obtain approval may differ from that required to
obtain FDA approval. Approval by the FDA does not ensure approval by regulatory authorities in
other countries or jurisdictions, and approval by one foreign regulatory authority does not ensure
approval by regulatory authorities in other foreign countries or by the FDA. The foreign regulatory
approval process may include all of the risks associated with obtaining FDA approval. We may not
obtain foreign regulatory approvals on a timely basis, if at all.
Risks Relating to Collaborators
We need to establish additional collaborative alliances in order to succeed.
We seek to advance some of our products through collaborative alliances with pharmaceutical
companies. Collaborators provide the necessary resources and drug development experience to advance
our compounds in their programs. Upfront payments and milestone payments received from
collaborations help to provide us with the financial resources for our internal research and
development programs. Our internal programs are focused on developing TLR-targeted drug candidates
for the potential treatment of infectious diseases, autoimmune and inflammatory diseases, cancer,
and respiratory diseases. We are also advancing our GSO technology for potential application as
research reagents and as therapeutic agents. We believe that additional resources will be required
to advance compounds in all of these areas. If we do not reach agreements with additional
collaborators in the future, our ability to advance our compounds will be jeopardized and we may
fail to meet our business objectives. If we cannot enter into additional collaboration agreements,
we may not be able to obtain the expertise and resources necessary to achieve our business
objectives. We face, and will continue to face, significant competition in seeking appropriate
collaborators. Moreover, collaborations are complex and time consuming to negotiate, document, and
implement. We may not be successful in our efforts to establish and implement collaborations or
other alternative arrangements. The terms of any collaborations or other arrangements that we
establish, if any, may not be favorable to us.
31
Table of Contents
Our existing collaborations and any collaborations we enter into in the future may not be
successful.
An important element of our business strategy includes entering into collaborative alliances
with corporate collaborators, primarily large pharmaceutical companies, for the development,
commercialization, marketing, and distribution of some of our drug candidates. In December 2007, we
entered into an exclusive, worldwide license agreement with Merck KGaA to research, develop, and
commercialize products containing our TLR9 agonists for treatment of cancer, excluding cancer
vaccines. In December 2006, we entered into an exclusive license and research collaboration with
Merck to research, develop, and commercialize vaccine products containing our TLR7, 8, and 9
agonists in the fields of cancer, infectious diseases, and Alzheimers disease.
Any collaboration that we enter into may not be successful. The success of our collaborative
alliances, if any, will depend heavily on the efforts and activities of our collaborators. Our
existing collaborations and any potential future collaborations have risks, including the
following:
| our collaborators may control the development of the drug candidates being developed with our technologies and compounds including the timing of development; | ||
| our collaborators may control the public release of information regarding the developments, and we may not be able to make announcements or data presentations on a schedule favorable to us; | ||
| disputes may arise in the future with respect to the ownership of rights to technology developed with our collaborators; | ||
| disagreements with our collaborators could delay or terminate the research, development or commercialization of products, or result in litigation or arbitration; | ||
| we may have difficulty enforcing the contracts if any of our collaborators fail to perform; | ||
| our collaborators may terminate their collaborations with us, which could make it difficult for us to attract new collaborators or adversely affect the perception of us in the business or financial communities; | ||
| our collaboration agreements are likely to be for fixed terms and subject to termination by our collaborators in the event of a material breach or lack of scientific progress by us; | ||
| our collaborators may have the first right to maintain or defend our intellectual property rights and, although we would likely have the right to assume the maintenance and defense of our intellectual property rights if our collaborators do not, our ability to do so may be compromised by our collaborators acts or omissions; | ||
| our collaborators may challenge our intellectual property rights or utilize our intellectual property rights in such a way as to invite litigation that could jeopardize or invalidate our intellectual property rights or expose us to potential liability; | ||
| our collaborators may not comply with all applicable regulatory requirements, or may fail to report safety data in accordance with all applicable regulatory requirements; | ||
| our collaborators may change the focus of their development and commercialization efforts. Pharmaceutical and biotechnology companies historically have re-evaluated their priorities following mergers and consolidations, which have been common in recent years in these industries. For example, we have a strategic partnership with Merck, which merged with Schering-Plough, which has been involved with certain TLR-targeted research and development programs. Although the merger has not affected our partnership with Merck to date, management of the combined company could determine to reduce the efforts and resources that the combined company will apply to its strategic partnership with us or terminate the strategic partnership. The ability of our products to reach their potential could be limited if our collaborators decrease or fail to increase spending relating to such products; |
32
Table of Contents
| our collaborators may under fund or not commit sufficient resources to the testing, marketing, distribution or development of our products; and | ||
| our collaborators may develop alternative products either on their own or in collaboration with others, or encounter conflicts of interest or changes in business strategy or other business issues, which could adversely affect their willingness or ability to fulfill their obligations to us. |
Given these risks, it is possible that any collaborative alliance into which we enter may not
be successful. Collaborations with pharmaceutical companies and other third parties often are
terminated or allowed to expire by the other party. For example, effective as of February 2010,
Novartis International Pharmaceutical, Ltd. terminated the research collaboration and option
agreement that we entered into with it in May 2005. Merck may terminate its license and research
collaboration agreement by giving us 90 days advance notice. Merck KGaA may terminate its license
agreement with us at its convenience by giving us 90 days advance notice. The termination or
expiration of either of these agreements or any other collaboration agreement that we enter into in
the future may adversely affect us financially and could harm our business reputation.
Risks Relating to Intellectual Property
If we are unable to obtain patent protection for our discoveries, the value of our technology and
products will be adversely affected.
Our patent positions, and those of other drug discovery companies, are generally uncertain and
involve complex legal, scientific, and factual questions. Our ability to develop and commercialize
drugs depends in significant part on our ability to:
| obtain patents; | ||
| obtain licenses to the proprietary rights of others on commercially reasonable terms; | ||
| operate without infringing upon the proprietary rights of others; | ||
| prevent others from infringing on our proprietary rights; and | ||
| protect our trade secrets. |
We do not know whether any of our patent applications or those patent applications that we
license will result in the issuance of any patents. Our issued patents and those that may be issued
in the future, or those licensed to us, may be challenged, invalidated or circumvented, and the
rights granted thereunder may not provide us proprietary protection or competitive advantages
against competitors with similar technology. Moreover, intellectual property laws may change and
negatively impact our ability to obtain issued patents covering our technologies or to enforce any
patents that issue. Because of the extensive time required for development, testing, and regulatory
review of a potential product, it is possible that, before any of our products can be
commercialized, any related patent may expire or remain in force for only a short period following
commercialization, thus reducing any advantage provided by the patent.
Because patent applications in the United States and many foreign jurisdictions are typically
not published until 18 months after filing, or in some cases not at all, and because publications
of discoveries in the scientific literature often lag behind actual discoveries, neither we nor our
licensors can be certain that we or they were the first to make the inventions claimed in issued
patents or pending patent applications, or that we or they were the first to file for protection of
the inventions set forth in these patent applications.
As of March 31, 2011, we owned 75 U.S. patents and U.S. patent applications and 232
corresponding patents and
patent applications throughout the rest of the world for our TLR-targeted immune modulation
technologies. These
33
Table of Contents
patents and patent applications include novel chemical compositions of matter
and methods of use of our IMO compounds, including IMO-2125, IMO-3100 and IMO-2055. With respect to
IMO-2125, we have issued patents that cover the chemical composition of matter of IMO-2125 and
methods of its use, with the earliest composition claims expiring in 2026. With respect to
IMO-3100, we have patent applications that cover the chemical composition of matter of IMO-3100 and
methods of its use that, if issued, would expire at the earliest in 2026. With respect to IMO-2055,
we have issued patents that cover the chemical composition of matter of IMO-2055 and methods of its
use, including in combination with marketed cancer products, with the earliest composition claims
expiring in 2023. With respect to IMO-4200, we have patent applications that cover the chemical
composition of matter of IMO-4200 and methods of its use that, if issued, would expire at the
earliest in 2027.
As of March 31, 2011, we owned four U.S. patent applications and one worldwide patent
application for our GSO compounds and methods of their use. Patents issuing from these patent
applications, if any, would expire at the earliest in 2030.
In addition to our TLR-targeted and GSO patent portfolios, we are the owner or hold licenses
of patents and patent applications related to antisense technology. As of March 31, 2011, our
antisense patent portfolio included 101 U.S. patents and patent applications and 149 patents and
patent applications throughout the rest of the world. These antisense patents and patent
applications include novel compositions of matter, the use of these compositions for various genes,
sequences and therapeutic targets, and oral and other routes of administration. Some of the patents
and patent applications in our antisense portfolio were in-licensed. These in-licensed patents
expire at various dates ranging from 2014 to 2022.
Third parties may own or control patents or patent applications and require us to seek licenses,
which could increase our development and commercialization costs, or prevent us from developing or
marketing products.
Although we have many issued patents and pending patent applications in the United States and
other countries, we may not have rights under certain third party patents or patent applications
related to our products. Third parties may own or control these patents and patent applications in
the United States and abroad. In particular, we are aware of third party United States patents that
contain broad claims related to the use of certain oligonucleotides for stimulating an immune
response, although we do not believe that these claims are valid. In addition, there may be other
patents and patent applications related to our products of which we are not aware. Therefore, in
some cases, in order to develop, manufacture, sell or import some of our products, we or our
collaborators may choose to seek, or be required to seek, licenses under third-party patents issued
in the United States and abroad or under third party patents that might issue from United States
and foreign patent applications. In such an event, we would be required to pay license fees or
royalties or both to the licensor. If licenses are not available to us on acceptable terms, we or
our collaborators may not be able to develop, manufacture, sell or import these products.
We may lose our rights to patents, patent applications or technologies of third parties if our
licenses from these third parties are terminated. In such an event, we might not be able to develop
or commercialize products covered by the licenses.
Currently, we have not in-licensed any patents or patent applications related to our
TLR-targeted drug candidate programs or our GSO compounds and methods of their use. However, we are
party to seven royalty-bearing license agreements under which we have acquired rights to patents,
patent applications, and technology of third parties in the field of antisense technology, which
may be applicable to our TLR antisense. Under these licenses we are obligated to pay royalties on
net sales by us of products or processes covered by a valid claim of a patent or patent application
licensed to us. We also are required in some cases to pay a specified percentage of any sublicense
income that we may receive. These licenses impose various commercialization, sublicensing,
insurance, and other obligations on us.
Our failure to comply with these requirements could result in termination of the licenses.
These licenses generally will otherwise remain in effect until the expiration of all valid claims
of the patents covered by such licenses or upon earlier termination by the parties. The issued
patents covered by these licenses expire at various dates ranging from
2014 to 2022. If one or more of these licenses is terminated, we may be delayed in our
efforts, or be unable, to
34
Table of Contents
develop and market the products that are covered by the applicable
license or licenses.
We may become involved in expensive patent litigation or other proceedings, which could result in
our incurring substantial costs and expenses or substantial liability for damages or require us to
stop our development and commercialization efforts.
There has been substantial litigation and other proceedings regarding patent and other
intellectual property rights in the biotechnology industry. We may become a party to various types
of patent litigation or other proceedings regarding intellectual property rights from time to time
even under circumstances where we are not practicing and do not intend to practice any of the
intellectual property involved in the proceedings. For instance, in 2002, 2003, and 2005, we became
involved in interference proceedings declared by the United States Patent and Trademark Office for
some of our antisense and ribozyme patents. All of these interferences have since been resolved. We
are neither practicing nor intending to practice the intellectual property that is associated with
any of these interference proceedings.
The cost to us of any patent litigation or other proceeding even if resolved in our favor,
could be substantial. Some of our competitors may be able to sustain the cost of such litigation or
proceedings more effectively than we can because of their substantially greater financial
resources. If any patent litigation or other proceeding is resolved against us, we or our
collaborators may be enjoined from developing, manufacturing, selling or importing our drugs
without a license from the other party and we may be held liable for significant damages. We may
not be able to obtain any required license on commercially acceptable terms or at all.
Uncertainties resulting from the initiation and continuation of patent litigation or other
proceedings could have a material adverse effect on our ability to compete in the marketplace.
Patent litigation and other proceedings may also absorb significant management time.
Risks Relating to Product Manufacturing, Marketing and Sales, and Reliance on Third Parties
Because we have limited manufacturing experience, and no manufacturing facilities or
infrastructure, we are dependent on third-party manufacturers to manufacture drug candidates for
us. If we cannot rely on third-party manufacturers, we will be required to incur significant costs
and devote significant efforts to establish our own manufacturing facilities and capabilities.
We have limited manufacturing experience and no manufacturing facilities, infrastructure or
clinical or commercial scale manufacturing capabilities. In order to continue to develop our drug
candidates, apply for regulatory approvals, and ultimately commercialize products, we need to
develop, contract for or otherwise arrange for the necessary manufacturing capabilities.
We currently rely upon third parties to produce material for nonclinical and clinical testing
purposes and expect to continue to do so in the future. We also expect to rely upon third parties
to produce materials that may be required for the commercial production of our products. Our
current and anticipated future dependence upon others for the manufacture of our drug candidates
may adversely affect our future profit margins and our ability to develop drug candidates and
commercialize any drug candidates on a timely and competitive basis. We currently do not have any
long term supply contracts.
There are a limited number of manufacturers that operate under the FDAs current Good
Manufacturing Practices, or cGMP, regulations capable of manufacturing our drug candidates. As a
result, we may have difficulty finding manufacturers for our products with adequate capacity for
our needs. If we are unable to arrange for third-party manufacturing of our drug candidates on a
timely basis, or to do so on commercially reasonable terms, we may not be able to complete
development of our drug candidates or market them.
Reliance on third-party manufacturers entails risks to which we would not be subject if we
manufactured drug candidates ourselves, including:
35
Table of Contents
| reliance on the third party for regulatory compliance and quality assurance; | ||
| the possibility of breach of the manufacturing agreement by the third party because of factors beyond our control; | ||
| the possibility of termination or nonrenewal of the agreement by the third party, based on its own business priorities, at a time that is costly or inconvenient for us; | ||
| the potential that third-party manufacturers will develop know-how owned by such third party in connection with the production of our drug candidates that becomes necessary for the manufacture of our drug candidates; and | ||
| reliance upon third-party manufacturers to assist us in preventing inadvertent disclosure or theft of our proprietary knowledge. |
Any contract manufacturers with which we enter into manufacturing arrangements will be subject
to ongoing periodic, unannounced inspections by the FDA, or foreign equivalent, and corresponding
state and foreign agencies or their designees to ensure compliance with cGMP requirements and other
governmental regulations and corresponding foreign standards. One of our contract manufacturers
notified us that it had received a GMP warning letter from the FDA in February 2011. Any failure by
our third-party manufacturers to comply with such requirements, regulations or standards could lead
to a delay in the conduct of our clinical trials, or a delay in, or failure to obtain, regulatory
approval of any of our drug candidates. Such failure could also result in sanctions being imposed,
including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals,
product seizures or recalls, imposition of operating restrictions, total or partial suspension of
production or distribution, or criminal prosecution.
Additionally, contract manufacturers may not be able to manufacture our drug candidates at a
cost or in quantities necessary to make them commercially viable. To date, our third-party
manufacturers have met our manufacturing requirements, but we cannot be assured that they will
continue to do so. Furthermore, changes in the manufacturing process or procedure, including a
change in the location where the drug substance or drug product is manufactured or a change of a
third-party manufacturer, may require prior FDA review and approval in accordance with the FDAs
cGMP and NDA/BLA regulations. Contract manufacturers may also be subject to comparable foreign
requirements. This review may be costly and time-consuming and could delay or prevent the launch of
a drug candidate. The FDA or similar foreign regulatory agencies at any time may also implement new
standards, or change their interpretation and enforcement of existing standards for manufacture,
packaging or testing of products. If we or our contract manufacturers are unable to comply, we or
they may be subject to regulatory action, civil actions or penalties.
We have no experience selling, marketing or distributing products and no internal capability to do
so.
If we receive regulatory approval to commence commercial sales of any of our drug candidates,
we will face competition with respect to commercial sales, marketing, and distribution. These are
areas in which we have no experience. To market any of our drug candidates directly, we would need
to develop a marketing and sales force with technical expertise and with supporting distribution
capability. In particular, we would need to recruit a large number of experienced marketing and
sales personnel. Alternatively, we could engage a pharmaceutical or other healthcare company with
an existing distribution system and direct sales force to assist us. However, to the extent we
entered into such arrangements, we would be dependent on the efforts of third parties. If we are
unable to establish sales and distribution capabilities, whether internally or in reliance on third
parties, our business would suffer materially.
36
Table of Contents
If third parties on whom we rely for clinical trials do not perform as contractually required or as
we expect, we may not be able to obtain regulatory approval for or commercialize our products and
our business may suffer.
We do not have the ability to independently conduct the clinical trials required to obtain
regulatory approval for our drug candidates. We depend on independent clinical investigators,
contract research organizations and other third-party service providers in the conduct of the
clinical trials of our drug candidates and expect to continue to do so. We contracted with contract
research organizations to manage our recently completed Phase 1 clinical trials of IMO-2125 in
patients with chronic HCV infection and our Phase 1 clinical trials of IMO-3100 in healthy subjects
and expect to contract with such organizations for future clinical trials. We rely heavily on these
parties for successful execution of our clinical trials, but do not control many aspects of their
activities. We are responsible for ensuring that each of our clinical trials is conducted in
accordance with the general investigational plan and protocols for the trial. Moreover, the FDA and
foreign regulatory agencies require us to comply with certain standards, commonly referred to as
good clinical practices, and applicable regulatory requirements, for conducting, recording, and
reporting the results of clinical trials to assure that data and reported results are credible and
accurate and that the rights, integrity, and confidentiality of clinical trial participants are
protected. Our reliance on third parties that we do not control does not relieve us of these
responsibilities and requirements. Third parties may not complete activities on schedule, or at
all, or may not conduct our clinical trials in accordance with regulatory requirements or our
stated protocols. The failure of these third parties to carry out their obligations could delay or
prevent the development, approval, and commercialization of our drug candidates. If we seek to
conduct any of these activities ourselves in the future, we will need to recruit appropriately
trained personnel and add to our infrastructure.
The commercial success of any drug candidates that we may develop will depend upon the degree of
market acceptance by physicians, patients, third-party payors, and others in the medical community.
Any products that we ultimately bring to the market, if they receive marketing approval, may
not gain market acceptance by physicians, patients, third-party payors or others in the medical
community. If these products do not achieve an adequate level of acceptance, we may not generate
significant product revenue and we may not become profitable. The degree of market acceptance of
our drug candidates, if approved for commercial sale, will depend on a number of factors,
including:
| the prevalence and severity of any side effects, including any limitations or warnings contained in the products approved labeling; | ||
| the efficacy and potential advantages over alternative treatments; | ||
| the ability to offer our drug candidates for sale at competitive prices; | ||
| relative convenience and ease of administration; | ||
| the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; | ||
| the strength of marketing and distribution support and the timing of market introduction of competitive products; and | ||
| publicity concerning our products or competing products and treatments. |
Even if a potential product displays a favorable efficacy and safety profile, market
acceptance of the product will not be known until after it is launched. Our efforts to educate
patients, the medical community, and third-party payors on the benefits of our drug candidates may
require significant resources and may never be successful. Such efforts to educate the marketplace
may require more resources than are required by conventional technologies marketed by our
competitors.
37
Table of Contents
If we are unable to obtain adequate reimbursement from third-party payors for any products that we
may develop or acceptable prices for those products, our revenues and prospects for profitability
will suffer.
Most patients rely on Medicare, Medicaid, private health insurers, and other third-party
payors to pay for their medical needs, including any drugs we may market. If third-party payors do
not provide adequate coverage or reimbursement for any products that we may develop, our revenues
and prospects for profitability will suffer. Congress enacted a limited prescription drug benefit
for Medicare recipients in the Medicare Prescription Drug, Improvement, and Modernization Act of
2003. While the program established by this statute may increase demand for our products if we were
to participate in this program, our prices will be negotiated with drug procurement organizations
for Medicare beneficiaries and are likely to be lower than we might otherwise obtain. Non-Medicare
third-party drug procurement organizations may also base the price they are willing to pay on the
rate paid by drug procurement organizations for Medicare beneficiaries.
A primary trend in the United States healthcare industry is toward cost containment. In
addition, in some foreign countries, particularly the countries of the European Union, the pricing
of prescription pharmaceuticals is subject to governmental control. In these countries, pricing
negotiations with governmental authorities can take six months or longer after the receipt of
regulatory marketing approval for a product. To obtain reimbursement or pricing approval in some
countries, we may be required to conduct a clinical trial that compares the cost effectiveness of
our drug candidates or products to other available therapies. The conduct of such a clinical trial
could be expensive and result in delays in commercialization of our products. These further
clinical trials would require additional time, resources and expenses. If reimbursement of our
products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory
levels, our prospects for generating revenue, if any, could be adversely affected and our business
may suffer.
In March 2010, the U.S. Congress passed and President Obama signed into law the Patient
Protection and Affordable Care Act and the Health Care and Education Reconciliation Act. These
health care reform laws are intended to broaden access to health insurance; reduce or constrain the
growth of health care spending, especially Medicare spending; enhance remedies against fraud and
abuse; add new transparency requirements for health care and health insurance industries; impose
new taxes and fees on certain sectors of the health industry; and impose additional health policy
reforms. Among the new fees is an annual assessment beginning in 2011 on makers of branded
pharmaceuticals and biologics, under which a companys assessment is based primarily on its share
of branded drug sales to federal health care programs. Such fees could affect our future
profitability. Although it is too early to determine the effect of the new health care legislation
on our future profitability and financial condition, the new law appears likely to continue the
pressure on pharmaceutical pricing, especially under the Medicare program, and may also increase
our regulatory burdens and operating costs.
Third-party payors are challenging the prices charged for medical products and services, and
many third-party payors limit reimbursement for newly-approved health care products. These
third-party payors may base their coverage and reimbursement on the coverage and reimbursement rate
paid by carriers for Medicare beneficiaries. Furthermore, many such payors are investigating or
implementing methods for reducing health care costs, such as the establishment of capitated or
prospective payment systems. Cost containment pressures have led to an increased emphasis on the
use of cost-effective products by health care providers. In particular, third-party payors may
limit the indications for which they will reimburse patients who use any products that we may
develop. Cost control initiatives could decrease the price we might establish for products that we
or our current or future collaborators may develop or sell, which would result in lower product
revenues or royalties payable to us.
We face a risk of product liability claims and may not be able to obtain insurance.
Our business exposes us to the risk of product liability claims that is inherent in the
manufacturing, testing, and marketing of human therapeutic drugs. We face an inherent risk of
product liability exposure related to the testing of our drug candidates in human clinical trials
and will face an even greater risk if we commercially sell any products. Regardless of merit or
eventual outcome, liability claims and product recalls may result in:
38
Table of Contents
| decreased demand for our drug candidates and products; | ||
| damage to our reputation; | ||
| regulatory investigations that could require costly recalls or product modifications; | ||
| withdrawal of clinical trial participants; | ||
| costs to defend related litigation; | ||
| substantial monetary awards to clinical trial participants or patients, including awards that substantially exceed our product liability insurance, which we would then have to pay using other sources, if available, and would damage our ability to obtain liability insurance at reasonable costs, or at all, in the future; | ||
| loss of revenue; | ||
| the diversion of managements attention away from managing our business; and | ||
| the inability to commercialize any products that we may develop. |
Although we have product liability and clinical trial liability insurance that we believe is
adequate, this insurance is subject to deductibles and coverage limitations. We may not be able to
obtain or maintain adequate protection against potential liabilities. If we are unable to obtain
insurance at acceptable cost or otherwise protect against potential product liability claims, we
will be exposed to significant liabilities, which may materially and adversely affect our business
and financial position. These liabilities could prevent or interfere with our commercialization
efforts.
Risks Relating to an Investment in Our Common Stock
Our corporate governance structure, including provisions in our certificate of incorporation and
by-laws, our stockholder rights plan and Delaware law, may prevent a change in control or
management that stockholders may consider desirable.
Section 203 of the Delaware General Corporation Law and our certificate of incorporation,
by-laws, and stockholder rights plan contain provisions that might enable our management to resist
a takeover of our company or discourage a third party from attempting to take over our company.
These provisions include:
| a classified board of directors; | ||
| limitations on the removal of directors; | ||
| limitations on stockholder proposals at meetings of stockholders; | ||
| the inability of stockholders to act by written consent or to call special meetings; and | ||
| the ability of our board of directors to designate the terms of and issue new series of preferred stock without stockholder approval. |
In addition, Section 203 of the Delaware General Corporation Law imposes restrictions on our
ability to engage in business combinations and other specified transactions with significant
stockholders. These provisions could have the effect of delaying, deferring or preventing a change
in control of us or a change in our management that stockholders may consider favorable or
beneficial. These provisions could also discourage proxy contests and make it more difficult for
you and other stockholders to elect directors and take other corporate actions. These provisions
could also limit the price that investors might be willing to pay in the future for shares of our
common stock.
39
Table of Contents
Our stock price has been and may in the future be extremely volatile. In addition, because an
active trading market for our common stock has not developed, our investors ability to trade our
common stock may be limited. As a result, investors may lose all or a significant portion of their
investment.
Our stock price has been volatile. During the period from January 1, 2010 to April 29, 2011,
the closing sales price of our common stock ranged from a high of $6.94 per share to a low of $2.32
per share. The stock market has also experienced significant price and volume fluctuations,
particularly within the past three years, and the market prices of biotechnology companies in
particular have been highly volatile, often for reasons that have been unrelated to the operating
performance of particular companies. The market price for our common stock may be influenced by
many factors, including:
| timing and results of nonclinical studies and clinical trials of our drug candidates or those of our competitors; | ||
| the regulatory status of our drug candidates; | ||
| failure of any of our drug candidates, if approved, to achieve commercial success; | ||
| the success of competitive products or technologies; | ||
| regulatory developments in the United States and foreign countries; | ||
| our success in entering into collaborative agreements; | ||
| developments or disputes concerning patents or other proprietary rights; | ||
| the departure of key personnel; | ||
| variations in our financial results or those of companies that are perceived to be similar to us; | ||
| our cash resources; | ||
| the terms of any financing conducted by us; | ||
| changes in the structure of healthcare payment systems; | ||
| market conditions in the pharmaceutical and biotechnology sectors and issuance of new or changed securities analysts reports or recommendations; and | ||
| general economic, industry, and market conditions. |
In addition, our common stock has historically been traded at low volume levels and may
continue to trade at low volume levels. As a result, any large purchase or sale of our common stock
could have a significant impact on the price of our common stock and it may be difficult for
investors to sell our common stock in the market without depressing the market price for the common
stock or at all.
As a result of the foregoing, investors may not be able to resell their shares at or above the
price they paid for such shares. Investors in our common stock must be willing to bear the risk of
fluctuations in the price of our common stock and the risk that the value of their investment in
our stock could decline.
ITEM 6. EXHIBITS.
The list of Exhibits filed as part of this Quarterly Report on Form 10-Q is set forth on the
Exhibit Index immediately preceding such Exhibits, and is incorporated herein by this reference.
40
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the
registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly
authorized.
IDERA PHARMACEUTICALS, INC. |
||||
Date: May 5, 2011 | /s/ Sudhir Agrawal | |||
Sudhir Agrawal | ||||
Chairman, President and Chief Executive
Officer (Principal Executive Officer) |
||||
Date: May 5, 2011 | /s/ Louis J. Arcudi, III | |||
Louis J. Arcudi, III | ||||
Chief Financial Officer (Principal Financial and Accounting Officer) |
||||
Exhibit Index
Exhibit No. | ||
10.1
|
Director Compensation Program. | |
31.1
|
Certification of Chief Executive Officer pursuant to Exchange Act Rules 13a-14 and 15d-14, as adopted pursuant to Section 302 of Sarbanes-Oxley Act of 2002. | |
31.2
|
Certification of Chief Financial Officer pursuant to Exchange Act Rules 13a-14 and 15d-14, as adopted pursuant to Section 302 of Sarbanes-Oxley Act of 2002. | |
32.1
|
Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |
32.2
|
Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
41